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Manganese (Mn) is a trace metal that is essential for optimal functioning of 
mammalian systems. However, excessive exposure to Mn is known to cause an 
extrapyramidal disease. Presently, Mn-induced neurotoxicity has no cure. In these 
studies, we examined the effectiveness of creatine therapy on models of Mn 
neurotoxicity. Primary astrocytes were cultured and divided into five groups: controls 
(CN), Mn group (300 μM MnCl2 for 24 hour), creatine group (1 mM creatine 
monohydrate for 24 hour), Mn followed by creatine treatment group (MnCr), and creatine 
treatment followed by Mn exposure group (CrMn). Results showed a significant increase 
in Mn concentrations in Mn and CrMn groups (p < 0.05), with Mn group showing a 
significant decrease in cellular viability and creatine attenuating the toxic effects of Mn in 
the MnCr and CrMn groups. A significant elevation in glutamate-aspartate transporter 
gene expression was seen in CrMn compared to CN, and glutathione peroxidase (GPx) 
gene expression was significantly decreased in MnCr and CrMn groups. Based on this 
study, we concluded that creatine may have some sort of neuroprotection in Mn-exposed 
primary cultured astrocytes. Following the astrocyte study, four brain regions from male 
Sprague-Dawley rats exposed to 1 g MnCl2 /L in water (Mn; n=6), given intraperitoneal 
injections of 75 g/kg body weight monohydrate creatine (Cr; n=6), or exposed to Mn and 
creatine injections (MnCr; n=6), or received no creatine injection with no exposure to Mn 
(CN; n=6) were dissected and processed. The effect of waterborne exposure to Mn and 
creatine treatment on gene expression profiles showed a statistical trend for an increase in 
glutamate-transporter-1 gene expression in MnCr group in the globus pallidus (GP) 
(p=0.066) and caudate-putamen (CP) (p=0.052) when compared to CN. A statistical trend 
for increased GPx gene expression was observed in Cr group of the substania nigra (SN) 
(p= 0.055) and MnCr group of cortex (CX) (p=0.051). Heme oxygenase-1 (HMX-1) in 
the Mn group of SN showed a statistical trend for increased gene expression (p= 0.072) 
when compared to CN, and GP showed a statistical trend towards an increased HMX-1 
expression in Mn group (p = 0.08) when compared to MnCr group. Finally, brain 
cytosolic creatine kinase gene expression was significantly lowered in the MnCr group of 
SN when compared to CN. Our study suggests that subchronic waterborne exposure to 
Mn does not cause significant changes on markers of oxidative stress and creatine 
treatment exerts some neuroprotection overall. 
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CHAPTER I 
INTRODUCTION 
 
 
Manganese (Mn) is an essential metal that is required in low concentrations for 
normal physiological functioning. However, excessive exposure to Mn through air or 
water results in its toxic accumulation in the brain leading to a parkinsonian syndrome 
known as manganism. The risk of exposure to toxic levels of Mn is not only 
occupational; but rather it has become an environmental concern, and the risk includes 
patients with liver disease, iron-deficient individuals, and even children. In adults, 
behavioral changes are early manifestations of Mn neurotoxicity, which later progress 
into neurological motor abnormalities that include dystonia, hypokinesia, gait, and 
rigidity.  
The pathophysiology of Mn neurotoxicity is complex and not well understood. 
The localization of Mn in the basal ganglia leads to the disruption of normal 
neurotransmission and results in subsequent neurodegeneration. The mechanistic basis of 
Mn toxicity is thought to be due to its deposition in the mitochondria, where it is reported 
to cause mitochondrial dysfunction by interfering in energy metabolism and increasing 
reactive oxygen species (ROS). Furthermore, it is reported that high levels of Mn may 
alter signaling pathways within the cell, as well as alter transcription and translation of 
particular proteins in neuronal and glial cells. The homeostasis of glutamate (GLU), the  
major excitatory neurotransmitter in the brain, is also documented to be greatly affected 
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by Mn. The excessive extracellular accumulation of GLU in manganism is hypothesized 
to be due to increased GLU release, and\or decreased extracellular rate of clearance. 
These changes are suggested to occur as a result of attenuated uptake of GLU by 
glutamate-aspartate transporter (GLAST) and glutamate transporter-1 (GLT-1), which are 
the most predominant GLU transporters in the brain.  
Providing mechanisms for mitochondrial protection is thought to prevent energy 
deficits, minimize ROS generation and protect the cells against apoptosis, which would 
minimize neurodegeneration. Recently, the use of creatine as a neuroprotective agent has 
emerged in both Parkinson’s disease and Huntington’s disease. Current research supports 
the successful ability of creatine to protect against GLU excitotoxicity and mitochondrial 
dysfunction by buffering ATP depletion, preventing neuronal cell death, and activating 
antiapoptotic signaling pathways. 
There are three primary goals for this study: 1) examine the role of creatine 
treatment on the survival of Mn-exposed astrocytes; 2) examine the cause of Mn-induced 
GLU excitotoxicity in rat brain, and explore the effectiveness of creatine treatment in 
attenuating the effect of Mn; and 3) examine the effect of Mn on oxidative stress markers 
with or without creatine treatment. The specific aims for this study are: 
1. Examine the role of creatine treatment on the survival of Mn-exposed astrocytes. 
Treatment of cortical astrocytes with creatine before and after Mn exposure. The 
working hypothesis for this aim is that creatine will protect astrocytes against 
mitochondria-derived cell death by providing an exogenous substrate for ATP 
synthesis. 
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2. Examine the cause of Mn-induced GLU excitotoxicity in rat brain, and to 
explore the effectiveness of creatine treatment in attenuating the effect of Mn. 
Twenty-one day old Sprague-Dawley rats were used to measure in vivo gene 
expression and protein levels of GLAST and GLT-1, and measure gene expression of 
brain creatine kinases in multiple brain regions as well as plasma creatine kinase 
activity. The working hypothesis for this aim is that high levels of Mn may alter 
GLU transporters gene expression and proteins leading to GLU excitotoxicity and 
creatine will attenuate Mn effect by sparing energy deficiency in the cell and by 
increasing creatine kinases expression and activity.  
3. Examine the effect of Mn on oxidative stress markers with or without creatine 
treatment. Twenty-one day old Sprague-Dawley rats were used to measure in vivo 
protein levels of glutathione (GSH), and the gene expression of heme oxyogenase-1 
(HMX-1). The working hypothesis for this aim is that high levels of Mn may alter 
GSH protein levels and HMX-1 gene expression due to increased cellular oxidative 
stress and creatine will attenuate the neurotoxic effect of Mn. 
The general hypothesis of this study is that toxic levels of Mn may cause GLU 
excitotoxicity through alterations in GLU transporters. This excitotoxicity along with 
Mn-induced mitochondrial damage would subsequently result in increased ROS 
production and downstream events that lead to overall neurodegeneration. The use of 
creatine in Mn-exposure may help attenuate these changes by preventing energy 
metabolism impairment and ROS generation. Results from this study may elucidate the 
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role of Mn in neurodegenerative processes, and may provide insight into a new 
therapeutic agent. 
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CHAPTER II 
REVIEW OF LITERATURE 
 
 
Introduction 
Manganese (Mn) is an essential metal found in soil, water, and air. Although it 
exists in low concentrations within mammalian systems, Mn is important for normal 
physiological functioning. 
Manganese has 11 oxidation states from -3 to +7. However, only Mn+2, Mn+3, and 
Mn+4 are found in mammals (Archibald and Tyree, 1987). In humans, Mn acts as a 
structural component for some metalloenzymes, these include arginase and superoxide 
dismutase (SOD). Manganese also acts as an activator of numerous enzymes, such as 
glutamine synthetase, which is responsible for the synthesis of glutamine from glutamate 
(GLU) (Keen et al., 2000). These roles make Mn essential for the metabolism of 
carbohydrates, lipids, and proteins. Moreover, Mn is important for growth, immune and 
skeletal development, and is vital for digestive and reproductive health. 
Being an essential nutrient, Mn is obtained from the diet. The adequate intake 
(AI) of Mn has been established at 2.3 and 1.8 mg/day for adult men and women, 
respectively, with an increased intake for children and pregnant and lactating women 
(Aschner and Aschner 2005; ATSDR, 2009). 
Manganese deficiency has not been reported in clinical settings; rather it has been 
seen in domestic animals and has been induced in lab animals causing metabolic 
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impairment, defective growth and abnormal skeletal development (Finley and Davis, 
1999). On the other hand, excessive exposure to Mn causes a neurodegenerative disorder, 
known as manganism. This disorder, which resembles Parkinson’s disease, is 
characterized by the accumulation of Mn in the brain causing symptoms such as, tremors, 
bradykinesia, dystonia, postural instability, gait abnormalities, insomnia, impotence, 
decreased memory and cognitive abilities, anxiety and symptoms of psychoticism 
(Mergler et al., 1994; Bowler et al., 2006). 
Though cases of manganism have been predominantly reported in welders and 
miners, there is a growing concern of environmental exposure to toxic levels of Mn. This 
concern has been growing with the emerging use of Mn as a fuel additive in the form of 
methylcyclopentadienyl manganese tricarbonyl (MMT). Furthermore, highly populated 
areas that are located near Mn-emitting plants are also at risk of exposure to toxic levels 
of Mn via polluted air and water. 
Manganese Exposure 
Dietary Sources and Daily Requirements 
Plants are an abundant source of Mn, specifically because Mn serves as the last 
electron accepter in the electron transport chain in photosynthesis. Whole grains, 
legumes, seeds and nuts are all Mn-rich plant sources.  
Due to limitations on human research and the absence of clinical cases of Mn 
deficiency, no recommended dietary allowance has been established for Mn. However, in 
1980 the National Research Council has determined the Estimated Safe and Adequate 
Daily Dietary Intake, which was set at 2.5-5 mg intake/day for adults (Friedman et al., 
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1987). Moreover, due to the increasing concerns of Mn toxicity, the Environmental 
Protection Agency (EPA) has developed a dietary reference dose (RfD) of                   
0.14 mg.kg-1.d-1. Based on a body weight of 70 kg, the EPA’s RfD for dietary intake of 
Mn was set at 10 mg/day and for drinking water at 4.2 mg/day (Friedman et al., 1987; 
Finley and Davis, 1999). As mentioned previously, the most recent approach to 
determine safe intake levels of Mn was conducted by the National Academy of Sciences 
in 2001, which has established a newer AI of 2.3 and 1.8 mg Mn/day for adult males and 
females, respectively. However, during pregnancy and lactation, the need for Mn 
increases, indicating the importance of Mn for the development of the fetus and later the 
infant. Recommended AIs of Mn also vary for children depending on age and 
developmental stage (Aschner and Aschner, 2005). 
 Absorption 
Based on studies that have used radio-labeled Mn (54Mn), about only 1-5% of 
ingested Mn is absorbed in the gastrointestinal tract. There is a lot of controversy 
regarding the means of absorption. Some studies suggest an active transport mechanism, 
while others suggest a non-saturable passive diffusion (Aschner et al., 2005). However, it 
is known that Mn absorption in the gut can be influenced by multiple factors. One factor 
is the amount of Mn in the diet. Increased Mn in the diet leads to several adaptations by 
the intestine to decrease the absorption of the metal (Britton et al., 1966; Aschner et al., 
2005), and causes other adaptations by the liver since the liver is responsible for 
regulating Mn turnover (Britton et al., 1966). Other factors that influence the absorption 
of Mn according to Davidsson et al. (1991) could include minerals (e.g. calcium), 
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phytates, and ascorbic acid. Nevertheless, iron (Fe) is considered one of the major 
effectors on Mn absorption and metabolism, where many human and animal studies 
throughout the years have demonstrated a possible interaction between Mn and Fe 
(Rossander-Hultén et al., 1991; Davis et al., 1992; Rodríguez-Matas et al., 1998). Finley 
et al. (1999) reported an inverse relationship between ferritin stores and Mn absorption in 
young women, where Fe deficiency enhances the absorption of Mn. Some researchers 
suggest competitive absorption and\or competitive transport (Aschner et al., 2005). 
Furthermore, gender difference in Mn absorption has been associated with the difference 
in ferritin stores among males and females (Finley et al., 1994). 
Toxic Exposure to Manganese 
Exposure to high concentrations of Mn leads to its subsequent accumulation in the 
brain, particularly in the basal ganglia. It has been found that Mn accumulates and 
damages the globus pallidus (GP), caudate-putamen (CP), substantia nigra (SN) and 
subthalamic nuclei (STN) of the basal ganglia leading to the extrapyramidal disorder, 
manganism (Yamada et al., 1986; Yu et al., 2003). 
Toxic Exposure via Diet 
There are no concerns of excessive exposure to Mn via oral ingestion in healthy 
individuals. Concerns only arise when the liver is either underdeveloped, such as in 
infancy, or when it is dysfunctional. Post absorption, Mn is delivered to the liver, which 
is responsible for regulating Mn excretion via bile (Papavasiliou et al., 1966). For infants, 
the risk arises with the use of milk formulas, which may have high levels of Mn (Aschner 
et al., 2005) or with the consumption of water from Mn-contaminated wells (Hafeman et 
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al. 2007; Bouchard et al., 2011). Multiple clinical cases of manganism have been 
observed in patients suffering of liver disease, particularly in chronic hepatic 
encephalopathy and cholestasis, where these patients developed neurological symptoms 
and had elevated blood Mn concentrations (Lazeyras et al., 2002; Burkhard et al., 2003). 
Symptoms of Mn overload have been observed in hospitalized patients receiving long-
term total parenteral nutrition, where Mn bypasses the liver’s normal regulation process 
(Fell et al. 1996; Masumoto et al., 2001). This is seen especially in children, patients 
suffering of liver disease, and patients with intestinal obstruction disorders (Staunton and 
Phelan, 1995; Bertinet et al. 2000). Finally, the effect of Fe deficiency on absorption of 
Mn lays a risk on the world’s huge Fe-deficient population. Finley and Davis (1999) 
suggested that the combination of a vegetarian diet with Fe deficiency could increase the 
risk of accumulating toxic levels of Mn in the body. Thus, given the world wide 
prevalence of Fe deficiency, the scenario of a large vulnerable population to Mn toxicity 
exists. 
Toxic Exposure via Air and Water 
1) Manganese as an Occupational Hazard 
Exposure to high levels of airborne Mn and its subsequent accumulation in the 
brain has been known since 1837, when the first cases of manganism were described in 
ore crushers (Rodier, 1955). Welders, miners, smelters, and workers in steel and battery 
production factories, who are exposed daily to Mn fumes and dust, are at a great 
occupational risk of accumulating Mn in the brain and developing subsequent 
neurological abnormalities (Crossgrove and Zheng, 2004). According to the United 
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States’ EPA, the risk of Mn airborne exposure increases in workers at Fe and steel 
production plants, power plants as well as coke ovens (U.S. EPA, TEACH, 2006). Thus, 
to prevent and decrease the occupational hazard of Mn, the Occupation Safety and Health 
Administration of the United States Department of Labor has established regulations to 
enforce a Permissible Exposure Limit of 5 mg/m3 ceiling in general, construction and 
maritime industries. Furthermore, the National Institute of Occupational Safety and 
Health of the Center of Disease Control and Prevention, has set the limits of a 
Recommended Exposure Limit at 1 mg/m3.  
2) Manganese as an Environmental Hazard 
Regardless of all regulations that have been established to prevent and decrease 
exposure at the occupational level, a great risk is posed on the public through 
environmental exposure. This risk is particular for those who dwell in areas that are near 
plants that release Mn-polluted air or water. Research supports the fact that there is an 
increased prevalence of Parkinson’s disease-related symptoms in populations near Mn-
producing industries (Lucchini et al., 2007; Catal´an-V´azquez et al., 2010). A study in 
Southern Ohio showed that living approximately 10 miles away from ferromanganese 
refinery led to subclinical impairment in postural balance due to exposure to low but 
chronic Mn levels in the air (Standridge et al., 2008). Another study in Mexico reported a 
significant correlation of changes in motor tests and airborne exposure to Mn in a 
population living near mining facilities (Catal´an-V´azquez et al., 2010). Furthermore, the 
effect of airborne environmental Mn exposure on children has revealed disturbing results 
of decreased intellectual abilities (Riojas-Rodriguez et al., 2010; Bouchard et al., 2011). 
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Manganese-contaminated drinking water, whether due to natural factors or to industrial 
waste or to the use of Mn-containing pesticides, has effects on birth outcomes, 
particularly causing low birth weight (Aschner et al., 2005). High levels of Mn in 
drinking water are also associated with decreased cognitive performance in children and 
to some extent in adults too (Bowler et al., 2006; Menezes-Filho et al., 2011). 
Another rising concern of the public’s environmental exposure is the use of Mn in 
the form of MMT as an antiknock agent in gasoline replacing the use of lead. The 
combustion of gasoline containing MMT would release Mn phosphates, Mn sulfates, and 
some Mn oxides into the air (Nelson et al., 2002). There is a lot of controversy when it 
comes to MMT and manganism. It has been suggested that the emission of Mn will 
contribute to the overall increase of Mn concentration in ambient air of urban areas 
(Davis et al., 1998). However, research reports that the amount of Mn released from 
vehicle emissions is too small to cause any clinical harm (Abbott, 1987). A study 
conducted in Toronto and Hamilton, two highly polluted cities that are heavily crowded 
with vehicle exhausts, have concluded that MMT in gasoline is not contributing to 
ambient air nor is it causing any neurological effects on subway workers, bus and taxi 
drivers, all who are in close proximity to exhaust air (Finkelstein and Jerrett, 2007). On 
the other hand, lab animals have shown neurological changes associated with MMT 
exposure (Salehi et al. 2006, Tapin et al, 2006). But it must be taken in account that the 
concentration of MMT used in these studies is at least 200 times more than its 
permissible concentration in the air of crowded cities that are known to use MMT (Taylor 
et al., 2006). 
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Transport of Manganese into the Brain 
There are a number of theories regarding the entry of Mn into the brain. Some of 
these theories have been proved by in vivo and in vitro studies, while some theories 
remain questionable. 
Inhalation: The Olfactory Neurons 
The entry of particle matters through the olfactory neurons to the brain allows 
bypassing the tight regulation of the blood brain barrier (BBB). Elder et al. (2006) 
reported a 3.5 fold increase in Mn content of the olfactory bulb after 12 days exposure to 
Mn oxide, and a 2 fold increase in the lung tissue. The increase in Mn was also noted in 
other brain regions that included caudate-putamen, cortex, and cerebellum. Exposure of 
rats to MnCl2 aerosols with one of the nostrils occluded revealed an increase in Mn levels 
in the olfactory bulb at the side of the open nostril compared to the occluded one 
(Brenneman et al., 2000). However, some researchers have reported that the travel of Mn 
through the olfactory will not necessarily lead to its accumulation in the caudate-putamen 
(CP), which is one of the brain regions that is usually targeted by Mn (Dorman et al., 
2002). Thus, the fact that the olfactory nerve may serve as a direct route for Mn transport 
and deposition in the brain is somewhat debatable. 
Inhalation: The Pulmonary Epithelium  
It has been observed that the lung epithelia is involved in absorbing and 
accumulating neurotoxic Mn levels in the brain of both lab animals and humans (Roels et 
al., 1987; Dorman et al., 2005). The deposition and absorption of Mn particles in the 
lungs depend on the size, the density of the molecule, and solubilization by macrophages 
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(Roth, 2006). Once Mn+2 is trapped in the alveolar lymphoid fluid, it would be either 
transported into the blood via transferrin or via nonselective calcium (Ca+2) channels but 
not by divalent metal transporter-1 (DMT-1) (Heilig et al., 2006). 
The Blood Brain Barrier and the Choroid Plexus  
Depending on its chemical form, Mn in the blood is found either bound to 
albumin (Mn+2), transferrin (Mn+3), or complexed to other molecules such as citrate and 
bicarbonate (Mn+2) (Harris and Chen, 1994). While the transport of Mn across the BBB is 
thought to be temperature, energy, pH, [Fe], and [Na+] -dependent (Fitsanakis et al., 
2006), it mainly depends on plasma Mn concentration. At normal physiological 
concentrations, it is suggested that Mn passes through the capillary endothelium of the 
BBB by either endocytosis (when complexed to citrate or transferrin), or through 
particular carriers on the endothelium such as DMT-1 and ZIP-8 (Crossgrove et al., 2003; 
Corssgrove and Yokel, 2004; Aschner et al., 2007). Some studies suggest the presence of 
particular Ca+2-dependant channels for Mn transport across the BBB (Corssgrove and 
Yokel, 2005). At high plasma concentrations, Mn was found to cross the BBB-cerebral 
spinal fluid barrier via the choroids plexus (Murphy et al. 1991; Rabin et al. 1993). Wang 
and others (2008) reported a predominant role of transferrin rather than DMT-1 in the 
transport of Mn into the choroids plexus. However, more research is needed to reach to a 
conclusion regarding the transport of Mn into the brain. 
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Manganese Neurotoxicity 
Manganese in the nervous tissue is normally found in low concentrations of 
approximately 1-2.9 μg/g dry weight, with the highest concentrations in the caudate- 
putamen (CP) and the globus pallidus (GP) (Prohaska et al., 1987; Bush et al., 1995). 
These regions, in addition to the substania nigra (SN), were reported to have significantly 
elevated Mn concentrations following Mn overload in nonhuman primates (Shinotoh et 
al., 1995; Guilarte et al., 2006). In Mn-exposed symptomatic and non-symptomatic 
workers, magnetic resonance imaging has shown an increase in the pallidal index, 
indicating high Mn deposition in the GP (Dietz et al., 2001; Kim et al., 1999). 
Furthermore, a 4 to 10 fold increase of Mn concentration was reported to be accompanied 
with significant neuronal atrophy in GP, and to a lesser extent in the CP (Maeda et al., 
1997). Marked gliosis was also reported with an increase in astrocytic cellular count and 
characteristic Alzheimer’s Type II astrocytes in humans and monkeys (Maeda et al., 
1997; Olanow et al., 1996). These alterations are associated with a disruption in the 
intracellular and extracellular neurotransmitter concentrations in the basal ganglia 
resulting in GLU excitotoxicity and decreased γ-aminobutyic acid (GABA) release from 
the CP and GP (Erikson and Aschner, 2003; Fitsanakis et al., 2006).  
On the cellular level, toxic amounts of Mn tend to accumulate significantly in the 
mitochondria (Gavin et al., 1990; 1992), and to a lesser degree in the nuclei (Morello et 
al., 2008). The accumulation of Mn in the mitochondria in basal and toxic conditions may 
suggest a role of this organelle in Mn homeostasis in the cell similar to its role in 
regulating calcium (Ca+2) (Gavin et al., 1999; Morello et al., 2008), and not merely due to 
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the localization of Mn-superoxide dismutase (SOD) in the matrix and inner membrane of 
the mitochondria as some suggested. The resulting mitochondrial dysfunction, 
particularly in astrocytes, is thought to contribute to the overall Mn neurotoxicity. 
Furthermore, studies have reported a role of Mn in inhibiting oxidative phosphorylation 
and generating reactive oxygen species (ROS), which results in cellular damage and 
energy metabolism impairment (Gavin et al., 1992; Milatovic et al., 2009). 
Mechanisms of Manganese Neurotoxicity 
Manganese induces neurotoxicity in the brain via multiple mechanisms. The 
accumulation of this metal in the basal ganglia, which is responsible for motor control, 
leads to impaired mitochondrial function, disrupted neurotransmission, increased 
oxidative stress, and subsequent cell death and neurodegeneration.  
1. Mitochondrial Dysfunction and Energy Deficiency 
The entry of Mn into the mitochondria occurs through the Ca+2 uniporter, where 
Mn tends to increase the uptake of Ca+2 (Gavin et al., 1992). High mitochondrial levels of 
Ca+2 inhibit Mn efflux resulting in its accumulation in the mitochondria, which in turn 
inhibits the exit of Ca+2 into the cytosol (Gavin et al., 1990; 1992). Therefore, Mn 
toxicity interferes with intracellular Ca+2 balance, and causes reduction in mitochondrial 
membrane potential (Milatovic et al., 2007), altogether leading to the subsequent opening 
of the mitochondrial permeability transition pore (mPTP) (Gunter et al., 1990). 
Studies that have investigated the effect of Mn on energy metabolism have 
reported a significant decline in ATP levels in in vitro models of Mn-induced 
neurotoxicity (Brouillet et al., 1993; Zwingmann et al., 2003). The accumulation of Mn in 
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the mitochondria has been reported to reduce the efficacy of oxidative phosphorylation in 
producing ATP possibly due to Mn-induced reduction in the activity of complex I in the 
electron transport chain (Galvani et al., 1995; Yoon et al., 2011). Additionally, a decline 
in the activity of the Kreb’s cycle enzymes and other mitochondria-related proteins has 
been reported in various Mn toxicity cell models (Zwingmann et al., 2003; Zhang et al., 
2005). These changes not only cause energy failure but also contribute to the increased 
cellular oxidative stress and play a role in the induction of apoptosis. 
Previous studies have also shown an increase in apoptosis and neuronal cell loss 
upon exposure to Mn (Hirata, 2002; Stanwood et al., 2009). In astrocytes, it has been 
documented that exposure to high levels of Mn result into the release of caspase-3 
(Gonzalez et al., 2008; Yin et al., 2008), and the up-regulation of Bcl-2 proteins 
(Gonzalez et al., 2008). Furthermore, Prabhakaran and colleagues (2009) reported an 
increase in the release of cytochrome c and an up-regulation of BNIP-3 proteins in 
dopaminergic cell lines. The increase in these markers of apoptosis indicates a significant 
role of the dysfunctional mitochondria in initiating cell death following intoxication with 
Mn.   
2. Altered Neurotransmission 
Neurotransmission in the basal ganglia is a highly complex system that is made 
up of interconnected inhibitory and excitatory pathways acting in coordination with the 
cerebral cortex to regulate movement. The basal ganglia receive excitatory input via the 
thalamus from the cerebral cortex, and sends inhibitory signals back. The major 
neurotransmitters that are part of the basal ganglia-thalamus-cerebral cortex circuit 
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include the inhibitory neurotransmitters γ-aminobutyric acid (GABA) and dopamine 
(DA), as well as the brain’s major excitatory neurotransmitter glutamate (GLU). 
As mentioned previously, Mn toxicity targets specific nuclei of the basal ganglia 
resulting in a movement disorder. It has been well-documented that Mn induces region-
specific neurochemical changes by disrupting the synthesis, metabolism, and transport of 
GABA, DA, and GLU neurotransmitters, where these changes depend on severity and on 
the route of Mn exposure (Fitsanakis et al., 2006). Zwingmann and colleagues (2003) 
have shown alterations in the synthesis of GLU and GABA upon exposure to Mn. 
Nonetheless, Mn seems to cause changes in neurotransmitter concentrations by mainly 
affecting the transport system (Zwingmann et al., 2004; 2007). Previously published data 
report changes in DA neuronal D1 and D2 receptors (Fitsanakis et al., 2006), and report 
alterations in GABA transporter and receptors as well (Anderson et al., 2007).  
Glutamate is tightly regulated in the CNS, where it must be kept at low 
concentrations in the extracellular fluid (ECF) to prevent excitotoxicity (Danbolt, 2001). 
The clearance of GLU from the ECF is a function of astrocytes, which express two high 
affinity Na+-dependent transporters; these are glutamate-aspartate transporter (GLAST) 
and glutamate transporter-1 (GLT-1). Once GLU enters the astrocytes, it can be 
converted into α-ketoglutarate, or it can be amidated by glutamine synthetase in the 
presence of ammonia into glutamine, which is later released into the ECF for uptake by 
neurons (Danbolt, 2001). Moreover, studies have revealed that excessive exposure to Mn 
mediates excitotoxicity, where several mechanisms may be involved (Fitsanakis and 
Aschner, 2005). 
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One of the suggested mechanisms for excitotoxicity in manganism is decreased 
post-synaptic clearance of GLU by astrocytes (Hazell and Norenberg, 1997), where these 
cells tend to be the first cell type to accumulate Mn (Aschner et al., 1992). This high 
affinity towards Mn is thought to be due to the exclusive presence of glutamine 
synthetase in astrocytes, where this enzyme accounts for 80% of the total Mn in the brain.  
The decrease in the uptake of GLU is attributed to dysfunction in the GLU transporters. 
Some studies have proposed non-competitive binding of Mn to the transporters leading to 
GLU transport inhibition (Hazell and Norenberg, 1997). Meanwhile, it is also suggested 
that disrupted ion homeostasis, particularly Na+ and K+, following Mn accumulation or 
the induction of ROS generation by Mn, may interfere the function of the GLU 
transporters (Hazell and Norenberg, 1997). Finally, it has been shown in previous studies 
that Mn disrupts gene and protein expression of GLAST and GLT-1 transporters, 
therefore suggesting Mn-induced genomic and post-translational modification of GLU 
transporters (Erikson and Aschner, 2002). 
3. Oxidative Stress  
Manganese is thought to have oxidant power similar to that of Fe in the Fenton 
reaction. Excess Mn+2 have been reported to induce formation of Mn+3, where the latter is 
thought to have a higher capacity for oxidative stress induction (Kenten and Mann, 
1957). In Mn neurotoxicity, Mn has been reported to contribute to the autoxidation of the 
CNS catecholamine such as DA (Lloyd, 1995), as well as fatty acids (Milatovic et al., 
2007 and 2009). However, the increased oxidative stress in Mn overload is not limited to 
the pro-oxidant activity of Mn, but could also be secondary to other events taking place in 
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the cell, such as mitochondrial damage (Milatovic et al., 2007; 2009), ion imbalance 
(Scheuhammer and Cherian, 1981), and excess GLU (Trotti et al., 1998). 
Although cells are equipped with defense mechanisms to scavenge ROS, Mn 
seems to alter antioxidant systems. For instance, levels of glutathione, a tripeptide 
antioxidant synthesized endogenously from GLU, cysteine, and glycine, were found to be 
altered upon airborne intoxication with Mn in rat and monkey brains (Taylor et al., 2006; 
Erikson et al., 2008). Liccione and Maines (1988) also reported changes in other related 
enzymes, such as glutathione peroxidase, glutathione reductase, as well as changes in 
catalase. 
Heme oxygenase (HMX) is the rate limiting enzyme in the breakdown of heme 
into biliverdin, which is a process that involves the release of free Fe and carbon 
monoxide (CO) as byproducts (Ryter and Tyrrell, 2000). While there are 3 isoforms of 
HMX in the brain, HMX-1 is the major isoform that is expressed in neurodegeneration. 
The regulatory region of the HMX-1 gene is characterized with a binding site for nuclear 
factor kappa B (NFҡB), as well as metal response elements, cadmium response elements, 
and stress response elements, therefore the upregulation of HMX-1 can be induced by 
various stimuli that include heme, heavy metals, H2O2 and oxidized lipid products 
(Dennery et al., 2000). The overexpression of HMX-1 that is observed in multiple 
neurodegenerative diseases is thought to play a role in cellular defense against oxidative 
damage (Schipper et al., 2009). This is attributed mainly to the antioxidant and anti-
inflammatory activity of byproducts of heme degradation, particularly bilirubin which 
results of biliveridin breakdown (Clark et al., 2000). While HMX-1 increased expression 
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is reported to have neuroportective effects against excitotoxicity and traumatic brain 
injury (Schipper et al., 2009), yet it is also found to induce cellular events that are 
harmful rather than protective. For instance, under certain conditions, the free Fe and CO 
that are released from the breakdown of heme contribute to increased oxidative stress and 
induce mitochondrial damage (Schipper et al., 2000). A recent study by Li and others 
(2011) investigated HMX-1 protein levels in PC12 cell model of Mn neurotoxicity and 
reported involvement of Mn in the activation of Nrf2 signaling pathway that leads to 
upregulation of HMX-1 gene expression. However, the role of HMX-1 and its expression 
in in vivo models of Mn neurotoxicity is unknown and is crucial for the understanding of 
the disrupted Fe metabolism that is reported in Mn toxicity. 
4. Other Mechanisms  
Manganese can also induce neurotoxicity by altering expression of various genes. 
This alteration occurs through the activation of inflammatory pathways as well as through 
the generation of free radicals that influence redox sensitive pathways (Chen et al., 2006). 
Moreover, Mn has been reported to disrupt Fe metabolism in the brain. Specifically, 
previous studies have reported an increase in Fe levels in the brain, therefore contributing 
in the neurotoxic events (Aschner et al., 2005; Chen et al., 2006). 
Therapies for Manganese Neurotoxicity 
The use of chelating agents has been the first therapy described for treating 
manganism (Humphreys, 1946). These agents work by binding metals, thereafter 
increasing their excretion rate and leading to accelerated metal removal. Calcium 
disodium versenate (CaNa2EDTA) is a chelating agent that has been used in treating 
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manganism (Herrero Hernandez et al., 2006; Jiang et al., 2006). Studies have found 
CaNa2EDTA to be effective in decreasing Mn blood levels by increasing urinary 
excretion (Jiang et al., 2006). Although research shows CaNa2EDTA to be a successful 
therapy for acute exposure to Mn, this might not be the case in chronic exposure, where 
CaNa2EDTA or any other chelating agents have no effect on restoring the integrity of the 
damaged tissue (Cook et al., 1974; Crossgrove and Zheng, 2004). Moreover, the majority 
of chelating agents including CaNa2EDTA chelate other trace metals, such as Fe and Cu 
leading to subsequent deficiencies. On the other hand, para-aminosalicylic acid (PAS), a 
drug used in treating tuberculosis, can act as a chelating agent through increasing Mn 
excretion via feces (Tandon et al., 1978). Para-aminosalicylic acid has been recently 
used in treating Mn and has yielded an overall improvement in neurological performance 
in cases of chronic Mn exposure (Ky et al., 1992; Jiang et al., 2006), which could be 
likely due to removal of Mn. A recently published study by Zheng et al. (2009) on rats 
receiving intraperitoneal injections of MnCl2, reported PAS to be effective in removing 
Mn without inducing Fe deficiency, however the exposure route used in this study is not 
a common route for excessive exposure to Mn. Furthermore, only few papers in the 
literature address the use of PAS in manganism, and hence more research is needed.  
Levodopa (L-dopa), a precursor of DA, is a drug used for treating Parkinson’s 
disease. L-dopa crosses the blood brain barrier and compensates the loss of DA in the 
brain. Clinical cases of manganism have yielded different outcomes with the use of L-
dopa (Huang et al., 1993; Kenangil et al., 2006; Lu et al., 1994). It has been reported that 
long term L-dopa treatment contributes to the severity of the disease rather than 
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alleviating symptoms, where in vivo studies have shown a significant increase in auto-
oxidation of L-dopa when co-administered with Mn (Serra et al., 2000). Thus, the use of 
L-dopa holds no promises for treating Mn neurotoxicity. 
Recent in vitro and in vivo approaches for treating toxicity of Mn have targeted 
the use of antioxidants, where they are hypothesized to enhance cellular response to Mn-
induced oxidative stress. Studies using dopaminergic cell lines have shown a protective 
role of N-acetyl-L-cysteine against Mn-induced apoptosis (Kitazawa et al., 2002; Zhang 
et al., 2009; Yoon et al., 2011). However, recent data from our lab show that treating Mn-
exposed rats with N-acetyl-L-cysteine did not yield any significant changes in profiles of 
oxidative stress markers, while treatment with epigallocatechin gallate, the prominent 
antioxidant found in green tea extract, had only limited benefits. Silymarin, an 
antioxidant flavonoid, has been found to attenuate Mn-induced cell death as well as 
improve endogenous antioxidant activity (Chtourou et al., 2010; 2011). Other recent 
therapies that are being tested in vitro include: cyclopentanone prostaglandin, an 
antitumor drug that is found to impose neuroprotective properties (Furuta et al., 2007; 
Shibata et al., 2009), as well as riluzole, which is a drug used in amyotrophic lateral 
sclerosis (ALS) to attenuate GLU excitotoxicity (Deng et al., 2009).  
While currently available therapies are not efficiently effective in curing and 
reversing symptoms of manganism, and while new emerging therapies tend to target only 
one mechanistic aspect of Mn neurotoxicity, there is a need for finding a therapy that 
would restore altered biochemical parameters and enhance cellular defense against Mn 
toxicity. 
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Creatine 
Creatine or methylguanidino-acetic acid is a guanidino compound that can be 
synthesized endogenously from arginine, methionine, and glycine. The synthesis of 
creatine requires a two-step reaction that involves two enzymes; arginine:glycine amidino 
transferase (AGAT) and S-adenosyl-L-methionine:N-guanidinoacetate methyltransferase 
(GAMT). 
 
 
These enzymes are only found in the liver, as well as in the kidney, pancreas, 
testes, and in the brain (Walker, 1979; Persky and Brazeau, 2001; Braissant et al., 2001). 
Creatine can also be obtained from the diet, where it is found abundantly in red meats and 
in fish (Balsom et al., 1994).   
Creatine is either synthesized endogenously depending on availability of AGAT 
and GAMT enzymes in the tissue or it can enter the cell from the blood circulation via 
Na+ and Cl- dependent creatine transporter-1 (CRT-1), where creatine is usually 
concentrated in tissues with high fluctuating energy demands, such as the skeletal 
muscles, the heart, and the brain, due to its critical role in energy homeostasis 
(Wallimann et al., 1992). Creatine kinases (CKs) are magnesium-dependent 
phosphotransferases that are found in different tissue-specific isoforms. These enzymes 
catalyze the hydrolysis of ATP, where they help dephosphorylate ATP into ADP 
allowing creatine to bind the phosphate group and form phosophcreatine (PCr), which is 
a storage form of energy. When there is a sudden demand for energy in the cell, CKs with 
L-arginine + glycine       AGAT           Guanidino acetate + ornithine 
Guanidino acetate + S-adenosyl methionine      GAMT       Creatine + S-adenosyl homocysteine 
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their low-threshold ADP sensor facilitate the reverse reaction, leading to the release of 
creatine and ATP. It is noteworthy that this energy system is the first to respond to energy 
needs within the cell, taking less time to release ATP than other energy systems such as 
glycolysis and oxidative phosphorylation (Walliman et al., 1992).  
Creatine in the Brain 
In the last few years, creatine has been targeted in neurodegenerative diseases due 
to its potential neuroprotective role in the brain. The brain is supplied with creatine either 
from the blood circulation, where creatine is capable of crossing the blood brain barrier 
through CRT-1, or it can be supplied by brain creatine synthesis. Recent data report 
expression of AGAT and GAMT in neurons, oligodendrocytes, and in astrocytes. It was 
suggested that the synthesis of brain creatine is restricted in astrocytes; however, a recent 
study by Braissant et al. (2011) has revealed that various cells in the CNS do not co-
express the two enzymes, which is indicative of the importance of neuro-astroglial 
interactions for the synthesis of creatine. Additionally, CRT-1 has been reported to be 
expressed in both neurons and oligodendrocytes; however it is unclear if astrocytes 
express this transporter (Braissant et al., 2001; Möller and Hamprecht, 1989). 
Creatine in Neurodegenerative Disorders 
Recently, approaches for the use of creatine as therapy in neurodegenerative 
diseases has emerged, where studies have been moved from the bench to patient 
bedsides, particularly in Huntington’s disease, amyotrophic lateral sclerosis (ALS), and 
in Parkinson’s disease. Animal models of Huntington's disease, an inherited 
neurodegenerative disease characterized with striatal excitatory lesions and oxidative 
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damage, have yielded positive results when treated with creatine. The results of these 
studies have shown enhanced animal survival, decreased rate of degeneration, improved 
motor performance, and increased ATP brain levels (Ferrante et al., 2000; Andreassen et 
al., 2001a; Dedeoglu et al., 2003). Moving creatine into the clinical setting, a trial by 
Bender and others (2005) has reported a decrease in GLU excitotoxicity in Huntington’s 
patients receiving 20 g/day for the first 5 days, and 6 g/day for the reminder of the study 
(10 weeks). In ALS, which is a neurodegenerative disorder characterized by 
mitochondrial dysfunction and cortical neuronal loss, creatine improved motor function 
in mice (Klivenyi et al., 1999), and decreased extracellular accumulation of GLU 
(Andreassen et al., 2001b). Moreover, in a phase I clinical trial of creatine, treatment with 
15 g creatine/day caused an increase in brain levels of creatine, and a decrease in GLU 
concentrations (Atassi et al., 2010). Creatine treatment in Parkinson’s disease seems to 
show promise in delaying the progression of the disease. As mentioned previously, 
Parkinson’s disease resembles manganism; however Parkinson’s disease is characterized 
with nigral neuronal damage rather than pallidal damage as observed in Mn 
neurotoxicity. Creatine has been shown to cause increased survival rate of cell models of 
Parkinson’s disease (Andres et al., 2005a; 2005b), and decrease in vivo biochemical 
alterations of key enzymes used as markers of oxidative stress (Matthews et al., 1999). In 
a clinical trial, creatine has led to improvement in overall patient mood and decreased 
required L-dopa dosage (Bender et al., 2006). Recently in 2007, the National Institute of 
Health (NIH) has announced a phase III clinical trial for the use of creatine in treating 
Parkinson’s disease (Bloom, 2007). Finally, more studies are conducted to determine a 
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possible role of creatine in treating ischemia (Zhu et al., 2004) and in improving 
cognition in elderly (Rawson and Venezia, 2011). 
Neuroprotective Mechanisms of Creatine 
The role of creatine in maintaining ATP\ADP ratio at equilibrium in the cell, and 
preventing energy deprivation during rapid bouts of neuroexcitation are thought to be the 
major reasons behind its neuroprotective ability. Furthermore, the constant supply of 
ADP into the mitochondrial matrix that follows the phosphorylation of creatine by 
mitochondrial creatine kinase (CK) is suggested to participate in decreasing ROS 
generation from oxidative phosphorylation (Meyer et al., 2006), where the latter is known 
to be the major source of ROS production in the cell (Chance et al., 1979).  
Besides its role in energy balance, creatine is thought to contribute to the 
regulation of neurotransmission. A study by Xu et al. (1996) has reported a PCr-
dependent uptake of GLU in synaptic vesicles in addition to the ATP-dependent uptake. 
Moreover, studies in models of Huntington’s and ALS have shown creatine 
supplementation to decrease GLU excitotoxicity (Bender et al., 2005, Andreassen et al., 
2001b). This attenuation of excitotoxicity is thought to be due to PCr providing energy 
that causes the restoration of Na+ gradient, which is needed for GLU active transport 
(Brustovetsky et al., 2001). Additionally, creatine has been found to alter the activity of 
GLU decarboxylase, where this enzyme is involved in the synthesis of GABA 
(Schultheiss et al., 1990; Peña-Altamira et al., 2005).  
One of the most controversial neuroprotective properties of creatine is its ability 
to prevent the formation of the mPTP, therefore delaying induction of apoptosis. The 
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octameric structure of the mitochondrial CK allows it to bind phospholipids in both the 
inner and outer mitochondrial membranes forming contact sites between these two 
membranes and allowing for mechanical stabilization (Speer et al., 2005). Furthermore, 
mitochondrial CK is found to be coupled with adenine nucleotide translocator (ANT), 
which participates in the events of the opening of the mPTP. A study conducted by 
Dolder and colleagues (2003) has reported an inhibition in the mPTP formation in 
isolated liver mitochondria expressing mitochondrial CK upon treatment with 10 mM 
creatine. However, this inhibition seems to be rather moderate as described in an in vitro 
study (Brustovetsky et al., 2001).  
Other suggested neuroprotective mechanisms of creatine include a possible 
antioxidant activity, where creatine has been reported to protect RNA against oxidative 
damage (Fimognari et al. 2009). Moreover, creatine is found to be involved in inducing 
signaling pathways within the cell such as NFҡB signaling pathway, which may explain 
the increase in survival rate in culture and animal studies (Juravleva et al., 2005). Finally, 
creatine has been found to play a role in cellular neuronal cell differentiation and 
development (Andres et al., 2005; Ducray et al., 2007), which is indicative of roles far 
beyond energy maintenance.  
Conclusion 
The exposure of vulnerable populations to toxic levels of Mn, whether 
occupational, environmental, or dietary, indicates a need to find a preventative approach 
to protect these populations, and to find a cure that would grant better prognosis for those 
who develop manganism. While Mn induces its toxicity through a number of 
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mechanisms that include oxidative stress, disrupted energy metabolism and 
neurotransmission, there is a constant need to find a therapeutic agent that would target 
all these mechanisms at once. Creatine, being considered for phase III clinical trial in 
Parkinson’s disease, might be such a therapeutic agent to cure or help prevent 
manganism. While creatine may not be able to chelate the metal, its ability to balance 
energy metabolism in the cell, and to protect against oxidative stress may bring forth the 
long awaited cure for manganism.   
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CHAPTER III 
EVALUATION OF CREATINE AS A NEUROPROTECTIVE AGENT AGAINST  
MANGANESE-INDUCED NEUROTOXICITY IN ASTROCYTES 
 
 
Abstract 
Manganism is a Parkinson’s-like neurodegenerative disorder that results from 
toxic accumulation of manganese (Mn) in the brain. It is well documented that astrocytes, 
which play a dynamic role in brain ion homeostasis and energy metabolism, are 
vulnerable to cytotoxicity caused by excessive Mn exposure. Currently, there are no 
known effective therapies to treat manganism; however, recently the use of creatine as a 
neuroprotective agent has emerged. Since astrocytes are the primary cells to respond to 
neurotoxins, we hypothesized that treating astrocytes with creatine prior to and after Mn 
exposure would decrease Mn-induced cytotoxicity and result in modulation of 
biomarkers of neurotoxicity that include creatine transporter (CRT-1), glutamate-
aspartate transporter (GLAST), and glutathione peroxidase (GPx). Primary astrocytes 
were cultured and divided into five groups: controls (CN), Mn group (300 μM MnCl2 for 
24 hours), creatine group (1 mM creatine monohydrate for 24 hours), Mn followed by 
creatine treatment group (MnCr), and creatine treatment followed by Mn exposure group 
(CrMn). Results show that cellular viability was significantly decreased in the Mn group 
(p < 0.05), and that creatine attenuated the toxic effects of Mn in the MnCr and CrMn 
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groups. The concentration of Mn was significantly elevated in Mn and CrMn groups, but 
not in MnCr group. A significant elevation in GLAST gene expression was seen in CrMn 
compared to CN, and GPx gene expression was significantly decreased in MnCr and 
CrMn groups, however there were no significant changes in CRT-1 gene expression due 
to either Mn or creatine exposures. In conclusion, it appears that the application of an 
exogenous source of creatine prior to or after Mn exposure may impose some sort of 
neuroprotection in primary cultured astrocytes.  
Introduction 
Manganese (Mn) is an essential metal that is needed for various physiological 
processes. However, excessive exposure to this metal may result in an extrapyramidal 
syndrome that resembles Parkinson’s disease. Manganese concentration in different brain 
tissue has been found to exceed 200 μM in monkey and rat models of Mn-induced 
neurotoxicity (Roels et al. 1997; Ingersoll et al., 1999; Lai et al., 1999). It is well 
documented in the literature that Mn exerts its neurotoxic effects through inducing 
oxidative stress (Taylor et al., 2006; Milatovic et al., 2007), and through disrupting 
normal neurotransmission (Fitsanakis et al., 2006) and energy metabolism (Zwingmann 
et al., 2003).  
Astrocytes are the housekeeping cells of the CNS; they are responsible for 
maintaining a balanced extracellular environment, which includes the clearance and 
recycling of the major excitatory neurotransmitter, glutamate. Two high affinity Na+-
dependent protein transporters are expressed on the cell surface of astrocytes for the 
uptake of glutamate. These are glutamate-aspartate transporter (GLAST) and glutamate 
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transporter-1 (GLT-1). Astrocytes are also responsible for the uptake of Mn, particularly 
due to glutamine synthetase enzyme, which is only found in astrocytes and is involved in 
the amination of glutamate to form glutamine, a key process in brain ammonia 
metabolism. In Mn neurotoxicity, astrocytes undergo alterations that lead to energy 
metabolism failure (Zwingmann et al., 2003), and changes in glutamate uptake (Hazell 
and Norenberg, 1997; Erikson and Aschner, 2002), which subsequently leads to excess 
extracellular fluid glutamate and excitotoxicity. Additionally, excessive exposure to Mn 
is reported to increase the generation of reactive oxygen species (ROS) and therefore 
contribute to cytotoxicity in astrocytes, where endogenous antioxidants fall short in 
protecting against these oxidative stressors, as their levels seem to be altered (Taylor et 
al., 2006). For instance glutathione, a thiol antioxidant that scavenges free radicals in the 
presence of glutathione peroxidase enzyme (GPx), has been found to decrease in neurons 
intoxicated with Mn (Zwingmann et al., 2003). 
Recently, the use of creatine in neurodegenerative disorders has emerged. 
Creatine has shown neuroprotection in models of Huntington’s disease (HD) (Ferrante et 
al., 2000; Dedeoglu et al., 2003), amyotrophic lateral sclerosis (ALS) (Klivenyi et al., 
1999), and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) models of Parkinson’s 
disease (Matthews et al., 1999). Creatine is a guanidino compound that is found in cells 
of high energy-fluctuating needs such as the skeletal muscles, brain, and heart. Creatine is 
either synthesized endogenously by the liver, and kidney or it is supplied through diet by 
consuming fish and fresh meat (Balsom et al., 1994). Synthesis of creatine in the CNS 
has been found to occur in both neuronal and glial cells, where expression of S-adenosyl-
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L -methionine:N-guanidinoacetate methyltransferase (GAMT) and L-arginine:glycine 
amidinotransferase (AGAT), the enzymes required for the synthesis of creatine from L-
arginine, has been documented (Dringen et al., 1998; Braissant et al., 2001). Creatine is 
used mainly as an energy buffer along with phosphocreatine (PCr). The transfer of a 
phosphate group from ATP to creatine to form PCr and ADP is carried out by both 
mitochondrial and cytosolic creatine kinases (CKs). When there is an increased demand 
for energy in the cell, CK transfers the phosphate group from PCr into ADP, to make 
more ATP readily available for the biological processes within the cell. Creatine is 
transported into the blood brain barrier through a creatine transporter (CRT-1). Several 
studies have reported the expression of CRT-1 in neurons and oligodendrocytes, but not 
in astrocytes (Braissant et al., 2001).   
Given the similarities between manganism and Parkinson’s disease, the promising 
neuroprotection of creatine on Parkinson’s disease by slowing down the disease 
progression as observed in clinical trials (NINDS NET-PD Investigators, 2006; 2008) 
may also be seen in models of Mn neurotoxicity, especially with the lack of an effective 
therapy for the latter. Therefore, it is important to investigate the use of creatine as a 
therapeutic agent for treating Mn-induced neurotoxicity and identify the underlying 
mechanisms of action. The purpose of this study was to evaluate the use of creatine in 
Mn neurotoxicity in astrocytes, and identify changes in gene expression of CRT-1, 
GLAST, and GPx genes.  
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Materials and Methods 
Cell Cultures 
Primary cortical astrocytes were obtained from GIBCO (Invitrogen, Carlsbad, 
CA). Briefly, the cells were isolated under sterile condition from the cortices of fetal 
Sprague-Dawley rats (gestation day 19), and grown in astrocyte growth medium (85% 
Dulbecco’s Modified Eagle medium (DMEM) containing 4.5 g/L glucose, and 15% Fetal 
Bovine Serum) before being cryopreserved and shipped in 90% astrocyte growth medium 
plus 10% DMSO. Afterwards, astrocytes pellet was thawed on ice, and cells were plated 
at 1 x 105 cell/mL density in a 6-well plate. Cell cultures were grown in DMEM 
containing 15% Fetal Bovine Serum, and maintained at 37 °C in humidified 95% air with 
5% CO2. Media was changed 2-3 times per week for 3 weeks until >95% confluence was 
achieved. Cells were divided into 5 groups treated as follows: (1) 24 hours 300 μM 
MnCl2 (Mn group), (2) 24 hours 1 mM creatine (Cr group), (3) 24 hours of 300 μM 
MnCl2, followed by 24 hours 1 mM creatine treatment (MnCr group), (4) 24 hours of 1 
mM creatine, followed by 24 hours of 300 μM MnCl2 (CrMn group), and (5) control 
group.  
MTT Viability Assay 
Cell viability was measured by using 3-(4, 5-dimethylthiazol-2-yl)-
2,5diphenyltetrazolium bromide (MTT) assay (Sigma Aldrich, Saint Louis, MO). After 
the end point of each treatment, the cell cultures were washed in PBS, and 1.5 ml DMEM 
media containing 150 μl MTT dissolved in DMEM (5 mg/ml) was added for each well. 
Cell cultures were then incubated at 37 °C in 5% CO2 incubator for 2 hours. Following 
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the incubation period, a 1.5 ml of MTT solubilization solution was added per well to 
dissolve formazan crystals. Thereafter, absorbance was measured with a plate reader 
wavelength of 550 nm, using a reference of 630 nm. 
Metals 
Astrocytes harvested in PBS were sonicated and Mn, Fe, and Cu concentrations 
were measured using graphite furnace atomic absorption spectrometry (Varian AA240, 
Varian, Inc., USA). 300 μl of cell homogenate was digested in 100 μl of ultrapure nitric 
acid for 48-72 hours in a sand bath at 60° C. An additional dilution with 2% nitric acid 
was made prior to the analysis. Bovine liver (NBS Standard Reference Material, USDC, 
Washington, DC) (10 μg Mn/g; 184 μg Fe/g; 80 μg Cu/g) was digested in ultrapure nitric 
acid and used as an internal standard for analysis (final concentration 5 μg Mn/L; 92 μg 
Fe/L; 40 μg Cu/L). 
RT-PCR 
At the end of the treatment periods, culture media was removed, and 1 ml of 
denaturation solution was added to each well. Cells were then harvested and sonicated. 
Messenger-RNA was isolated from the cells homogenates using ToTALLY RNA™ kit 
(Ambion Inc., Austin, TX) following the manufacturer’s instructions. Prior to cDNA 
synthesis, RNA concentration and purity were determined using A260:A280 ratio 
produced by NanoDrop spectrophotometry (Thermo Scientific, Delaware, MD). For 
cDNA synthesis, a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
Foster City, CA) was used as indicated in the manufacturer’s instructions guide. 
TaqMan® Gene Expression Assays were purchased to probe for GLAST, Creatine 
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transporter, and GPx gene expression, in conjunction with Universal PCR Master Mix 
(Applied Biosystems, Foster City CA). Triplicate aliquots of cDNA were analyzed on 96-
well plates using the expression assays for the genes of interest. All gene expression 
values were normalized to β-actin expression value from the same sample on the same 
plate and reported as percent of control.  
Statistics  
Data were analyzed using SPSS version 14 for windows (Chicago, IL). The 
analysis included using a two-way analysis of variance and two-tailed t-tests to detect 
differences among groups. Dunnett’s post hoc analysis was used to determine difference 
from controls when p <0.05. Outliers were removed via boxplot with ± 2 standard 
deviation criteria.To identify relationships between Mn concentrations and mRNA levels, 
two-tailed Pearson’s correlations analyses were conducted.  
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Results 
Metals Concentrations 
Mn was significantly elevated in Mn and CrMn groups (p<0.05) when compared 
to controls, whereas Cr and MnCr treatment did not significantly increase Mn levels 
(Table 3-1). Fe concentrations were significantly increased five-fold in CrMn when 
compared to control (p<0.05) but no other treatment caused elevated Fe levels. No  
significant treatment effects were observed with cellular Cu concentrations (Table 3-1).  
 
 
 
Group [Mn] [Fe] [Cu] 
Control 0.01998 ± 0.00379 0.07217 ±0.01330 
 
0.02270 ± 0.00260 
 
Mn only 
Creatine only 
MnCr 
CrMn 
2.35844 ± 0.04434* 
 
0.02259 ± 0.00207 
 
0.23189 ± 0.02215 
 
2.47759 ± 0.31734* 
0.04751 ± 0.00519 
 
0.07272 ± 0.00977 
 
0.08862 ± 0.02065 
 
0.37521 ± 0.15974*
0.01619 ± 0.00076 
 
0.01643 ± 0.00093 
 
0.02531 ± 0.00356 
 
0.01749 ± 0.00170 
*Statistically Significant at p < 0.05 Dunnet’s post hoc test. 
 
 
 
 
Table 3-1: Metal Concentrations 
 Manganese, iron, and copper concentrations in cultured astrocytes expressed as μg 
[Metal]/ mg protein ± S.E.M. 
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MTT Viability Assay 
The viability of astrocytes treated with Mn alone decreased significantly by ~ 
45% when compared to control (p<0.05) (Figure 3-1). Additionally, Mn group and MnCr 
group were significantly decreased when compared to Cr group, which was ~ 20% higher 
than controls. However, CrMn group, although lower than controls by ~ 20%, was not  
statistically significantly different from controls.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1: MTT Viability Assay. Mean group viability expressed as percent mean 
control in Mn, Creatine, MnCr, and CrMn primary astrocyte cultures. Mn exposure 
significantly decreased viability in Mn group. Creatine group seemed to have a slight 
increase in viability. MnCr and CrMn groups’ viability was elevated compared to 
manganese group, where the increase in viability was higher in CrMn than in MnCr. 
*Statistically Significant at p < 0.05 Dunnet’s post hoc test. 
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GPx Gene Expression  
A significant decrease in GPx gene expression was observed in MnCr and CrMn 
group (p <0.05) when compared to controls (Figure 3-2). However, this decrease along  
with the decrease in Mn group was not significantly correlated with Mn concentrations. 
 
 
 
 
 
 
 
 
 
 
Figure 3-2: GPx Gene Expression. Effect of Mn and creatine on glutathione peroxidase 
(GPx) gene expression in cultured astrocytes. Mn attenuated the gene expression of GPx 
in Mn, MnCr, and CrMn groups, where the decrease in the Mn-exposed Cr-treated 
astrocytes was statistically significant. *p<0.05 according to Dunnett’s post hoc analysis. 
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GLAST Gene Expression 
Although Mn group has shown a 50% decrease in GLAST gene expression when 
compared to control, this change was statistically not significant (Figure 3-3). However, a 
statistically significant increase was observed in CrMn group (p < 0.05). This increase  
did not show a correlation with Mn concentration. 
 
 
 
 
 
 
 
 
 
Figure 3-3: GLAST Gene Expression. Effect of Mn and creatine on glutamate:aspartate 
transporter (GLAST) gene expression. Mn caused a 50% non-significant decrease in 
GLAST gene expression when compared to controls. While exposure of astrocytes to Mn 
after being treated with creatine yielded a 3 fold increase in GLAST gene expression. 
*p<0.05 according to Dunnett’s post hoc analysis. 
 
 
 
 
 
0%
50%
100%
150%
200%
250%
300%
350%
Mn Cr MnCr CrMn
%
 C
on
tr
ol
GLAST Gene Expression
Mn
Cr
MnCr
CrMn
* 
40 
 
Creatine Transporter Gene Expression 
Results show an expression of CRT-1 in astrocytes. However, no significant 
changes were observed in CRT-1 gene expression upon exposure to Mn or treatment with  
creatine (Figure 3-4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4: CRT-1 Gene Expression. Effect of Mn and creatine on creatine transporter 
gene expression. Mn or creatine did not cause any changes in creatine transporter gene 
expression.  
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Discussion 
In this study we demonstrate the role of creatine in protecting against Mn 
cytotoxicity in astrocytes. Several novel findings emerged from this study. First, exposure 
of astrocytes to 300 μM of MnCl2 led to decreased viability, which corroborates previous 
studies using both lactate dehydrogenase assay and MTT assay (Yin et al., 2008), but 
creatine treatment prevented this loss of viability. Second, expression of GLAST trended 
to decrease in Mn, Cr, and MnCr group potentially affecting the uptake of glutamate; 
however there was a significant increase observed in CrMn group. Finally, GPx gene 
expression was decreased in all Mn exposed groups, which may lead to decreased GPx 
protein synthesis and thereafter disrupt glutathione (GSH) antioxidant cycle. Third, 
although CRT-1 was neither upregulated nor downregulated due to Mn-exposure, we 
report detectable levels of CRT-1 mRNA in primary cultured astrocytes. 
The 40% decrease in viability in the Mn group is similar to the decreased viability 
of other CNS cells exposed to Mn. Studies of rat brain endothelial cells (dos Santos et al., 
2010), dopaminergic cells (Prabhakaran et al., 2009), PC12 cells (Reaney and Smith, 
2005), and astrocytoma and neuroblastoma cell lines (Dukhande et al., 2006) all have 
demonstrated a decrease in viability upon treatment with at least 200 μM MnCl2, 
meanwhile the effect of creatine on astrocytic viability has not been examined. In MPTP-
exposed dopaminergic neurons, a 7 day treatment with 5 mM creatine was reported to 
increase neuronal viability by 1.32 folds when compared to controls (Andres et al., 
2005a). In a rat model of ALS, creatine decreased GABAergic neuronal death markers 
significantly, while in mice an overall increase in animal survival was observed (Peña-
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Altamira et al., 2005). Another study reported increased differentiation rather than 
viability in striatal GABAenrgic neurons in models of HD following 5 mM creatine 
treatment (Andres et al., 2005b). We repeated the experiment twice for validation, and 
similar results were yielded. Despite the inconsistent results in creatine treated Mn-
exposed groups, overall the viability of CrMn group was always higher than the viability 
of MnCr group regardless of the higher Mn concentrations measured in CrMn cells. This 
difference may indicate that pre-treatment with creatine exerts some protection against 
Mn neurotoxicity. However, for the MnCr group, it is possible that Mn has attenuated the 
effect of creatine. A recent study shows some evidence of this possible attenuation since 
Mn exposure led to a depletion of ATP (an important substrate for creatine biology) in 
astrocytes (Milatovic et al., 2007). Additionally, the creatine dosage used (1 mM) and 
exposure time (24 hours) might not have been sufficient enough to produce statistically 
significant changes.  
In situ hybridization has previously reported lack of CRT-1 gene expression in 
astrocytes (Braissant et al., 2001); however, using RT-PCR, we showed expression of 
CRT-1 in primary cultures astrocytes. It is possible that the in situ hybridization used in 
previous studies was not sensitive enough to detect mRNA levels; furthermore other 
studies that have treated cultured astrocytes with creatine have showed a response to 
creatine treatment. For instance, treatment of astrocytes with 5 mM of creatine attenuated 
the uptake of L-arginine (the rate limiting amino acid in creatine biosynthesis) by 
approximately 15% when compared to controls (Schmidlin and Wiesinger, 1994), and 
treatment of astrocytes with 25 mM of creatine delayed the toxic effects of 3-
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nitropropionic acid (Deshpande et al., 1997). These studies are indicative of the uptake of 
creatine by astrocytes.  
The concentration of the excitatory neurotransmitter glutamate is tightly regulated 
and maintained at low concentrations in the extracellular fluid of the CNS to prevent 
excitotoxicity (Rothstein et al., 1996). About 80% of the glutamate released in the 
synaptic space is taken up by astrocytes, where it is either committed to the glutamate-
glutamine cycle, or it’s committed to the TCA cycle (Danbolt, 2001). GLAST, one of the 
major glutamate transporters, is expressed in cultured astrocytes (Kondo et al., 1995). 
Changes in this transporter are thought to be the cause of decreased uptake of glutamate 
in Mn neurotoxicity, which eventually leads to excitotoxicity that is thought to contribute 
to Mn toxic effects. Previous studies have attributed the decrease in glutamate uptake to a 
possible binding of Mn to GLAST (Mutkus et al., 2005), or to a possible disruption in the 
electrochemical gradient that is related to GLAST regulation (Hazell and Norenberg, 
1997). Meanwhile, the decreased gene expression of GLAST upon Mn exposure could be 
another possibility for the decreased uptake of glutamate, where it has been previously 
reported that an overnight exposure to 500 μM of Mn decreases GLAST gene expression 
significantly (Erikson and Aschner, 2002). In another study, where Chinese hamster 
ovary cells were transfected with GLAST, exposure to 500 and 1000 μM of Mn for 18 
hours also resulted in a significant decrease in GLAST gene expression (Mutkus et al., 
2005). In this study, exposure of astrocytes to 300 μM Mn for 24 hours (Mn and MnCr 
groups) has shown a non-significant decrease in GLAST gene expression. However, 
CrMn group had a 3 fold increase in GLAST gene expression. While no direct 
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mechanism for this increase is known, we speculate that creatine treatment prior to Mn 
exposure may have provided sufficient energy reserves for particular signaling pathways 
that may have caused GLAST gene expression upregulation as a response to increased 
Mn levels in the cell. Moreover, creatine may have exerted an antioxidant role as has 
been suggested by recent studies, particularly in protecting nuclear DNA against 
oxidative damage, which thereby can affect gene regulation (Sestili et al., 2006; Guidi et 
al., 2008; Fimognari et al., 2009). 
 Since the induction of oxidative stress is a suggested mechanism for Mn 
neurotoxicity (Erikson et al., 2004; Milatovic et al., 2009), it is plausible that creatine 
could be providing cellular protection by preventing ROS generation. While 
excitotoxicity that results from the extracellular buildup of glutamate contributes to 
oxidative stress (Choi, 1988; Chen and Liao 2002), the accumulation of Mn in the 
mitochondria also plays part in cellular oxidative damage. The mitochondria are 
considered the main generator of ROS in the cell (Chance et al., 1979), and it is equipped 
with antioxidants that act to scavenge ROS. Glutathione is a ubiquitous tripeptide thiol 
that is known to participate in cellular detoxification against endogenous and exogenous 
oxidative stressors as well as other toxic molecules (Dringen et al., 2000). The reduced 
form of GSH reacts with ROS in the presence of GPx, to yield an oxidized glutathione 
disulfide (GSSH) and a reduced - less reactive – oxygen species. Changes in GSH have 
been reported in neurodegenerative disorders and have been associated with increased 
oxidative stress (Gegg et al., 2003). In Mn neurotoxicity, GSH has been reported to be 
decreased in the striatum of juvenile rats (Erikson 2005; 2006), and in elderly rats 
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(Desole et al., 1997; Erikson et al., 2004). Additionally, a decrease in GSH levels has 
been observed in human brain glioblastoma (Park and Park, 2010) and in rat brain 
microvessel endothelial cell lines (dos Santos et al., 2008) after being treated with 800 
μM of MnCl2. The decrease in total GSH could be a marker of increased activity due to a 
response to oxidative stress. This decrease can also be attributed to an increase in GPx 
synthesis or\and activity. Using gene expression as a marker of increased GPx synthesis, 
previous studies in our lab, have yielded no change in GPx gene expression accompanied 
with no change in total GSH levels in rats exposed to 1 mg/ml MnCl2 for 6 weeks via 
water (data not published). However, a study conducted on astrocytes by Chen and Liao 
(2002), reported a significant decrease in GPx gene expression in astrocytes when 
exposed to 500 μM of MnCl2 for 24 hours. In our experiment, we yielded similar results 
where GPx gene expression was decreased in all Mn exposed astrocytes, and this 
decrease was significant in the groups that received both, Mn and creatine (p<0.05), 
where creatine does not seem to exert any protective effect. It can be assumed that the 
decreased gene expression of GPx could be either a result of change in cellular signaling 
pathways or due to disruption of the GSH recycling. Depletion of GSH has been reported 
in the literature to modulate gene expression (Hammond et al., 2001; Kiyosawa et al., 
2007), therefore it can be speculated that the low levels of GSH may modify cellular 
signaling. Additionally, Mn has also been reported to cause changes in gene expression. 
A study using human primary astrocytes exposed to Mn, has documented a 60% decrease 
in glutathione reductase, the enzyme which is responsible for reducing GSSH back into 
GSH (Sengupta et al., 2007). Therefore, decreased glutathione reductase expression 
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and/or activity may lead to subsequent accumulation of GSSH that perhaps may give a 
negative feedback on GPx activity and gene expression. While creatine is thought to act 
as an antioxidant, a recent study by Juravleva et al. (2005) has demonstrated an effect of 
creatine on NFҡB signaling, leading to increased ROS generation rather than causing 
them to decrease. 
Creatine was first thought to exert its protective effects through maintaining a 
balanced ATP/ADP ratio; however recent evidence has shown that the role of creatine in 
neurological tissue extends beyond sustaining energy reserves. Creatine was found to 
inhibit the formation of mitochondrial permeability transition pore (PTP) (Dolder et al., 
2003), decrease generation of H2O2 by accelerating state 3 mitochondrial respiration 
(Meyer et al., 2006), and induce signaling pathways that enhance cell survival 
mechanisms (Juravleva et al., 2005). In Mn neurotoxicity, the accumulation of Mn in the 
mitochondria inhibits the efflux of calcium leading to an increased chance of PTP 
formation. Additionally, Mn was found to inhibit state 3 mitochondrial respiration by 
interfering with the function of Complex I of the electron transport chain (Galvani et al., 
1995). Furthermore, endogenous creatine has been reported to decrease upon Mn 
exposure in liver tissue of rats (Fordahl et al., 2011) and in brain cell cultures 
(Zwingmann et al., 2003). Therefore, it can be assumed that creatine treatment may 
protect the cells by 1) slowing down the formation of PTP. 2) Maintaining high ATP 
reserves that are needed for cellular survival and defense against Mn toxicity. 3) 
Reducing ROS generation in the mitochondria by increasing oxygen consumption. 4) 
Supplying an external source of creatine to replace depleted cellular stores. These 
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protective mechanisms of creatine are thought to require a functional CK. A study by 
Watts (1963) has previously reported a loss of CK activity upon addition of Mn to the 
purified enzyme, where Mn replaces the enzyme’s cofactor magnesium. Meanwhile, a 
study on MPTP Parkinson’s disease model deficient in mitochondrial CK has shown a 
neuroprotective effect of creatine, which may indicate that creatine neuroprotection may 
be independent from this enzyme. The effect of Mn on inhibiting both mitochondrial and 
cytosolic CK yet requires further investigation in an in vitro and in vivo model.  
In conclusion, our data indicate that supplementing astrocytes with creatine prior 
to exposure to toxic levels of Mn may prevent or delay the onset of neurotoxicity by 
enhancing the survival of astrocytes and providing a substrate for the storage of adequate 
amounts of ATP that is needed for optimal cellular functioning, especially for defense 
against potential insults. While the use of creatine in Mn neurotoxicity is novel, studies 
are needed to determine dose-effect relationships in different CNS cells. Additionally, the 
mechanisms of the neuroprotective effects of creatine require further attention and 
investigation. 
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CHAPTER IV 
EVALUTION OF THE USE OF CREATINE AS A NEUROPROTECTIVE 
AGENT AGAINST WATERBORNE MANGANESE-INDUCED  
NEUROTOXICITY IN THE RAT BRAIN 
 
 
Abstract 
Exposure to toxic levels of manganese (Mn) and its subsequent accumulation in 
the basal ganglia of the brain results in an extrapyramidal parkinsonian syndrome known 
as manganism. While Mn causes disrupted neurotransmission, oxidative injury and 
energy deficiency in the brain, and while there are no current treatments to reverse or 
alleviate the effect of Mn in vulnerable populations, there is constant need for research to 
find therapy for Mn-induced neurotoxicity. In the recent years, the use of creatine for 
treating neurodegenerative diseases surfaced with promising results. In this study, globus 
pallidus (GP), caudate-putamen (CP), substania nigra (SN) and cortex (CX) brain regions 
of male Sprague-Dawley rats exposed to 1 g MnCl2 /L in water (Mn; n=6), given 
intraperitoneal injections of 75 g/kg body weight monohydrate creatine (Cr; n=6), or 
exposed to Mn and at the same time received creatine injections (MnCr; n=6), or exposed 
to deionized water with no creatine injections (Cn; n=6) were dissected and processed. 
The effect of waterborne exposure to Mn and creatine treatment on gene expression 
profiles showed no changes on GLAST mRNA levels with a statistical trend for an 
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increase in GLT-1 gene expression in MnCr group GP (p=0.066) and CP 
(p=0.052) when compared to controls, while protein levels of both GLAST and GLT-1 
were not affected. A statistical trend for increased glutathione peroxidase gene expression 
was observed in Cr group of SN (p= 0.055) and MnCr group of CX (p=0.051), while 
there were no changes in total glutathione levels. Catalase gene expression was 
unaffected by Mn-exposure and Cr treatment; however, heme oxygenase-1 (HMX-1) in 
the Mn group of SN showed a statistical trend for increased gene expression (p= 0.072) 
when compared to controls, and GP showed a statistical trend towards an increase HMX-
1 expression in Mn group (p = 0.08) when compared to MnCr group. Upon examination 
of creatine related genes, it was revealed that both Cr and Mn exposures did not alter the 
gene expression of creatine transporter and mitochondrial creatine kinase, however, brain 
cytosolic creatine kinase was significantly lowered in the MnCr group of the SN when 
compared to controls. Finally, the activity of plasma creatine kinase was unchanged in all 
treatment groups compared to controls. Our study suggests that, subchronic waterborne 
exposure to Mn does not cause significant changes on markers of oxidative stress and 
creatine treatment exerts some neuroprotection.  
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Introduction 
Manganese (Mn) is a transient metal that is needed in trace amounts for sustaining 
activity and function of various key enzymes in the body, such as superoxide dismutase 
(SOD) and glutamine synthetase (GS). Manganese can be easily obtained from a diet rich 
in whole grains, legumes, and seeds. There is minimal evidence of Mn deficiency in 
humans; on the other hand, Mn toxicity leads to the development of a Parkinson’s–like 
syndrome, known as manganism. This neurodegenerative syndrome characterized with 
bradykinesia, dystonia, rigidity, and muscular tremors, occurs due to the accumulation of 
Mn in the basal ganglia, which constitutes of a number of nuclei that are major regulators 
of movement. Specifically, Mn tends to accumulate mostly in the globus pallidus (GP), 
followed by the caudate-putamen (CP) (Yamada et al., 1986; Yu et al., 2003). Excessive 
exposure to Mn could be either airborne, where inhalation of Mn-containing fumes 
increases the risk of Mn accumulation in the brain; as seen mainly in welders and alloy 
factory workers, or exposure to Mn could be waterborne, where long term consumption 
of water containing 1.8-14 mg Mn/L has been associated with increased prevalence of 
neurological symptoms in adults, declined intellect in children, and increased infant 
mortality (Kondakis et al., 1986; Hafeman et al., 2007; Bouchard et al., 201l),where this 
is especially seen in children living in underdeveloped countries. Furthermore, the risk 
increases in patients suffering from liver dysfunction or suffering from anemia.  
Upon its accumulation in the brain, Mn induces multiple alterations that 
subsequently lead to disturbed brain neurochemistry and to a putative loss of neuronal 
cells. One of the major changes that occur in the brain during Mn neurotoxicity is 
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modulation of neurotransmission in the brain, where Mn disrupts the metabolism and the 
uptake of glutamate (GLU), γ-aminobutyric acid (GABA), and dopamine. Glutamate is 
the major excitatory neurotransmitter in the brain; it is also a precursor for the synthesis 
of GABA. Extracellular levels of GLU must be maintained at low concentrations to 
prevent excitotoxicity (Danbolt, 2001). This clearance of GLU is carried out by 
astrocytes, where they metabolize GLU into glutamine through GS, which is an enzyme 
that requires Mn as a cofactor and that is responsible for 80% of Mn in the brain. Once 
glutamine is released from the astrocytes, it is taken up by neurons for the synthesis of 
either GLU or GABA depending on the type of neurons. The uptake of GLU into 
astrocytes is facilitated by active Na+-dependent transporters, most predominantly 
glutamate-aspartate transporter (GLAST), and glutamate transporter-1 (GLT-1). Gene 
and protein expressions of these transporters are disrupted in Mn neurotoxicity leading to 
decreased astrocytic uptake of GLU and subsequent excitotoxicity. A study by Erikson et 
al. (2002) showed a decrease in astrocytic mRNA levels of GLAST upon exposure to 
Mn, and other studies found decreased protein levels of GLAST as well as GLT-1 in 
monkeys intoxicated with Mn (Erikson et al., 2007; 2008).  
Besides altered neurotransmission and excitotoxicity, Mn causes an increased 
reactive oxygen species (ROS) generation. The tendency of Mn to accumulate in the 
mitochondria affects the mitochondrial physiology (Gavin et al., 1990), and disrupts 
energy metabolism (Zwingmann et al., 2003). It has been reported previously that Mn 
causes mitochondrial dysfunction by disrupting calcium homeostasis and by inhibiting 
enzymes involved in the electron transport chain as well as in the Kreb’s cycle, where 
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these changes contribute to increased oxidative stress, energy failure, and to the induction 
of apoptosis. Along with the free radicals that are generated from the mitochondria, Mn is 
thought to possess a pro-oxidant activity, where it causes auto-oxidation of dopamine 
(Florence and Stauber, 1989), and peroxidation of lipids (Avila et al., 2008). 
Furthermore, protective antioxidant systems in CNS cells are targeted by Mn 
neurotoxicity. For instance, levels of glutathione (GSH), a thiol antioxidant that 
scavenges free radicals in the presence of glutathione peroxidase (GPx), were reported to 
be changed in the CP, and cortex (CX) of monkeys exposed to Mn via air, where these 
changes were dependent on duration of exposure (Erikson et al., 2007; 2008). 
Additionally, other endogenous antioxidant systems such as metallothionein and SOD 
have been reported to be altered too (Erikson et al., 2006).  
Heme Oxygenase-1 (HMX-1) is an endoplasmic reticulum enzyme that is 
upregulated under oxidative stress conditions, where its correspondent gene is known to 
contain stress response elements and metal response elements, therefore rendering it 
sensitive for induction by pro-oxidants and by heavy metals (Dennery et al., 2000). Upon 
increased oxidative stress, there is an increase in “free heme pools” in the cell, where it is 
thought that the upregulation of HMX-1during stress is intended to protect against heme 
pro-oxidant activity by breaking it down into biliverdin, which further breaks down into 
bilirubin, where these two compounds are considered intracellular antioxidants (Ryter 
and Tyrrell, 2000). While the gene expression of this enzyme has been investigated in 
other neruodegenerative diseases, it is unknown whether it is upregulated during Mn 
neurotoxicity and whether it influences the disrupted metabolism of iron that has been 
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reported in previous studies. Catalase is an iron-dependent enzyme that acts as an 
antioxidant by converting H2O2 into H2O and O2 (Michiels et al., 1994). The activity of 
catalase has been previously reported to be altered (Liccione and Maines, 1988); 
therefore it is important to further investigate the effect of Mn-exposure on the gene 
expression of this antioxidant.  
Creatine is a guanidino compound that participates in cellular energy balance via 
the creatine-phosphocreatine shuttle. Whether synthesized intracellularly or taken up 
from the blood via creatine transporter (CRT-1), creatine obtains a phosphate group from 
ATP in a reaction catalyzed by creatine kinases (CKs), leading to the formation of 
phosphocreatine and ADP. Whenever a sudden increase for energy arises, CKs mobilize 
the reaction in the opposite direction generating ATP for energy demanding sites in the 
cell and releasing creatine. Interestingly, in the recent years this ergonomic compound, 
which is used mainly as a supplement for athletes, has been introduced as a potential 
neuroprotective agent against neurodegenerative disorders in lab as well as in clinical 
trials (Klivenyi et al., 1999; Matthews et al., 1999; Bender et al., 2005; 2006). It has been 
suggested that besides its contribution to cellular energy equilibrium, creatine has a 
potential to protect against mitochondria-induced apoptosis (Dodler et al., 2003). 
Furthermore, studies have proposed antioxidant activity of creatine (Fimognari et al. 
2009), and a possible involvement in key signaling pathways, such as NFҡB pathway 
(Juravleva et al., 2005). 
While there are no current treatments for Mn neurotoxicity, the successful 
emerging use of creatine in Parkinson’s disease that has a similar pathophysiology to 
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manganism, encourages the idea of investigating the use of creatine for treating Mn 
neurotoxicity. Therefore, the aims of this study are (1) to examine the use of creatine as a 
neuroprotective agent in an in vivo model of waterborne Mn exposure; (2) to investigate 
the effects of waterborne Mn exposure and creatine treatment on brain gene expression 
profiles of GLU transporters (GLAST and GLT-1), oxidative stress enzymes (GPx, 
catalase, and HMX-1), and on CKs as well as CRT-1; and (3) to identify brain changes in 
GLU transporters protein expression (GLAST and GLT-1), total GSH levels, and plasma 
CK activity. 
Materials and Methods 
Animals 
Male weanling (21 days old) Sprague-Dawley rats (Harlen Sprague-Dawley, 
Indianapolis, IN) (n= 24) were randomly divided into four groups: controls (Cn; AIN-
93G diet and deionized water), Mn-exposed controls (Mn; AIN-93G diet and deionized 
water containing 1 g MnCl2/ L), creatine-treated controls (Cr; AIN-93G diet and 
deionized water), and Mn-exposed creatine-treated group (MnCr; AIN-93G diet and 
deionized water containing 1 g MnCl2/ L). Diets were obtained from Dyets Inc. 
(Bethlehem, PA), and certified for metal content. The Mn-exposure protocol used has 
been previously proven in our lab to achieve brain Mn accumulation (Anderson et al., 
2007; 2008; Fordahl et al., 2010). Rats had free access to food and water 24 hour/day, 
and were housed in hanging cages in an animal facility with a typical dark light cycle 
(1800 hour - 0600 hour lights off) and a room temperature maintained at 25± 1 °C. 
Animals were acclimated for 1 week prior to the experiment. Creatine monohydrate 
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(Thermo Fisher Scientific, NJ) was dissolved in saline (30 mg/ml), and 75 mg/kg body 
weight was injected intraperitoneally in creatine-treated rats (Cr and MnCr groups), 
whereas other groups received only saline. At the end of the experiment (6 weeks), the 
rats were sacrificed, and brain tissue was dissected into the following regions: globus 
pallidus (GP), caudate-putamen (CP), substania nigra (SN) and cerebral cortex (CX). 
Tissues were quick frozen on dry ice, and stored at -80 °C for later use. All animal 
protocols were approved by the University of North Carolina at Greensboro Animal Care 
and Use Committee. 
Metal Analysis 
Concentrations of Mn and iron (Fe) were measured using graphite furnace atomic 
absorption spectrometry (Varian AA240, Varian, Inc., USA). Brain tissues were digested 
in ultrapure nitric acid (1:10, wt/vol. dilution) for 48-72 hours in a sand bath at 60° C. An 
additional dilution (1:20) with 2% nitric acid was made prior to the analysis. Bovine liver 
(NBS Standard Reference Material, USDC, Washington, DC) (10 μg Mn/g; 184 μg Fe/g) 
was digested in ultrapure nitric acid and used as an internal standard for analysis (final 
concentration 5 μg Mn/L; 92 μg Fe/L). 
RNA Isolation and cDNA Synthesis 
Tissues intended to be used for gene expression assays were submerged in 
RNAlater® solution (1:10 wt/vol dilution, Ambion Inc., Austin, TX), and stored at -80 
C° until analysis. After samples were homogenized, RNA was isolated using ToTALLY 
RNA™ kit (Ambion Inc., Austin, TX) following the manufacturer’s instructions. Prior to 
cDNA synthesis, RNA concentration and purity were determined using A260:A280 ratio 
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produced by NanoDrop spectrophotometry (Thermo Scientific, Delaware, MD). For 
cDNA synthesis, a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
Foster City, CA) was used, where 1 μg of total RNA was incubated with MultiScribe™ 
Reverse Transcriptase (50 U), 10✕ Random Primers, 25✕dNTP Mix (100 mM), and 
RNase Inhibitor at room temperature for 10 minutes followed by 1 hour at 37° C in a 
final volume of 20 μl. 
RT-PCR 
TaqMan® Gene Expression Assays were purchased to probe for GLAST, GLT-1, 
CRT-1, CK-BB, CK-Mit1, HMX-1, GPX, and catalase gene expression, in conjunction 
with Universal PCR Master Mix (Applied Biosystems, Foster City CA). Triplicate 
aliquots of cDNA were analyzed on 96-well plates using the expression assays for the 
genes of interest. All gene expression values were normalized to β-actin expression value 
from the same sample on the same plate and reported as percent of control. 
Protein Extraction 
Tissue samples were sonicated in 500 µl of RIPA lysis buffer (1% Nonidet 40, 
1% SDS, 0.5% sodium deoxycholate, 1 mM NaF, 2 mM ß-glycerolphosphate, 1 mM 
sodium orthovanadate, and 1X protease inhibitor cocktail (Chemicon, Houston, TX) in 
1X PBS) on ice until completely homogenized. Homogenates were incubated on ice for 
20 minutes before being centrifuged at 12,500 x g for 20 minutes at 4˚ C. Supernatant 
was then transferred to new tubes and used to determine total protein concentration by 
BCA assay (Pierce, Rockford, IL) before proceeding with western blot analysis. 
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Western Blot Analysis 
 Western blot analysis was conducted to examine the effects of manganese and 
creatine on the expression of GLAST and GLT-1 proteins in vivo. Protein samples (20 
µg) from GP and CP were combined with 4X LDS sample buffer (Invitrogen, Carlsbad, 
CA) containing 5% ß-mercaptoethanol and heated at 70˚ C in a heat block for 10 minutes. 
Samples were then loaded onto a 4-12% Bis-Tris pre-cast polyacrylamide mini gel 
(Invitrogen, Carlsbad, CA) and electrophoretically separated under denaturing conditions 
in 1X MES buffer containing 1% antioxidant (Invitrogen, Carlsbad, CA). Proteins were 
transferred to a PVDF membrane (Millipore, Billerica, MA) before blocking with 5% 
non-fat milk. Membranes were probed overnight at 4˚ C with primary antibody (rabbit 
polyclonal anti-rat GLAST 1:1500; rabbit polyclonal anti-rat GLT-1 1:4000; rabbit 
polyclonal anti-β-actin 1:8000, Alpha Diagnostics International, San Antonio, TX) for the 
protein of interest in 5% BSA. Membranes were rinsed in 1X TBST (10 mM Tris, pH 
7.4, 150 mM NaCl, 1.5% Tween 20) and probed for 2 hours at room temperature with an 
HRP-conjugated secondary antibody (goat anti-rabbit 1:10000, Alpha Diagnostics 
International, San Antonio, TX) in 5% BSA. Membranes were then rinsed several times 
in 1X TBST before incubation in ECL solution (Perkin Elmer, Waltham, MA) and 
exposure to radiographic film (Pierce, Rockford, IL). ß-actin housekeeping protein was 
probed on the membrane to attest equal loading of protein samples and for image 
analysis. Recombinant peptide controls for GLAST and GLT-1 were used to help identify 
target bands. Films were analyzed using image analysis software (ImageJ, NIH, 
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Bethesda, MD), with the amount of the target protein from each sample standardized to 
the amount of ß-actin from the sample.   
Total GSH 
Tissues were diluted 1:10 wt/vol. in phosphate buffered saline (pH 7.4). 
Following homogenization via sonication, the samples were centrifuged at 10,000 x g for 
15 minutes. Supernatant was transferred to new tubes and deproteinized by adding an 
equal amount of metaphosphoric acid (5 g dissolved in 50 ml water) (Sigma-Aldrich Inc., 
St. Louis, MO), then samples were vortexed for 30 seconds, and centrifuged at 3,000 x g 
for 2 minutes. To increase the sample pH, a 50 μl of 4 M triethalolamine (TEAM) 
(Sigma-Aldrich Inc., St. Louis, MO) was added per ml of supernatant. Total glutathione 
levels were measured immediately after the addition of TEAM reagent using Glutathione 
Assay Kit (Cayman Chemical, Ann Arbor, MI). Results are expressed as total glutathione 
equivalents per mg protein. 
Plasma CK Activity 
Creatine kinase colorimetric activity assay kit was obtained from BioAssay 
Systems (Haward, CA). Trunk blood was collected and centrifuged for 10 min at 12,000 
rpm speed. Plasma was then moved to new tubes and stored at -80° C. Later, the plasma 
samples were thawed and 10 μL of sample were mixed with 100 μL of the assay reagent. 
After 20 and 40 minutes incubation at 37° C, absorbance was measured at wavelength of 
340 nm. Calculations using absorbance of a provided calibrator and of water were used to 
determine creatine kinase activity expressed as unit per liter (U/L), where one unit is 
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equivalent to the transfer of 1 μmole of phosphate from phosphocreatine to ADP per min 
at pH 6.0. The assay was repeated twice with the samples ran in triplicates. 
Statistical Analysis 
Statistical analysis was conducted using SPSS version 14 for windows (Chicago, 
IL). Data were analyzed using a two-way ANOVA to detect differences among groups, 
and Dunnett’s post hoc analysis was used to determine difference from controls when p 
<0.05. Trends towards statistical significance were appointed at p <0.1. Outliers were 
removed via boxplot analysis with ± 2 standard deviation criteria. Two-tailed Pearson’s 
correlations analyses were conducted to identify relationships between Mn 
concentrations, protein and mRNA levels. 
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Results 
Metal Concentrations 
Levels of Mn were significantly elevated in Mn-exposed groups (Mn and MnCr) 
compared to controls in the GP and CP, whereas a non-significant increase was noted in 
SN and CX (Figure 4-1, Table 4-1). Approximately a 40% decrease in Mn concentration 
was observed in Cr group of GP when compared to control, however this change was not 
statistically significant. No changes were seen in Fe levels in the four brain regions 
(Figure 4-2, Table 4-2). 
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Table 4-1: Manganese Concentrations 
 GP CP SN CX 
CN 
Mn 
Cr 
MnCr 
0.2735503 ± 0.0364976 
0.5642267 ± 0.0635143* 
0.1664672 ± 0.0577272 
0.4822331 ± 0.0441297* 
0.3084356 ± 0.0193622 
0.5661074 ± 0.0447178* 
0.2986443 ± 0.0358098 
0.6715911 ± 0.1195424* 
  0.300782 ± 0.0653443 
0.5491050 ± 0.0679561 
 0.2511348 ± 0.0795295 
0.4101785 ± 0.0573310 
0.4064485 ± 0.0731025 
0.6296066 ± 0.1486872 
0.4437132 ± 0.2114589 
0.4456496 ± 0.048363 
Mn concentrations expressed as μg /g tissue. 
* Statistically significant at p < 0.05 
 
 
Table 4-2: Iron Concentrations 
 GP CP 
CN 
Mn 
Cr 
MnCr 
8.72122756 ± 1.4045252 
8.3267558 ± 1.6895308 
7.8352981 ± 1.2968245 
8.7575973 ± 1.6797409 
9.1133666 ±0.9971788 
10.16853 ± 1.5130574 
11.59390 ± 1.3702259 
11.216222 ± 0.8809103 
Fe concentrations expressed as μg / g tissue. 
* Statistically significant at p < 0.05 
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Figure 4-1: Brain Manganese Concentrations. Concentrations of Mn in the brain, 
where Mn values are expressed as percent control ± S.E.M. , where mean control values 
are equivalent to “100%”. Mn exposure significantly increased Mn accumulation in the 
(A) globus pallidus and (B) caudate-putamen versus control. Mn levels were increased 
also in Mn-exposed groups in (C) substania nigra and (D) cortex when compared to 
controls but without statistical significance. *p < 0.05 according to Dunnett’s post hoc 
analysis. 
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Figure 4-2: Brain Iron Concentrations. Concentrations of Fe in the brain, where Fe 
values are expressed as percent control ± S.E.M., where mean control values are 
equivalent to “100%”. Fe exposure was not altered in any of the treatment groups in (A) 
globus pallidus and (B) caudate-putamen when compare to control. *p < 0.05 according 
to Dunnett’s post hoc analysis. 
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GLAST and GLT-1 Gene Expressions 
GLAST gene expression did not change in any of the groups in all brain regions. 
On the other hand, GLT-1 gene expression yielded a statistical trend for an increase in 
MnCr groups of both the GP (p = 0.066) and CP (p = 0.052), when compared to controls. 
No changes were observed in other groups or in SN and CX (Figure 4-3). 
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Figure 4-3: Gene Expression of GLAST and GLT-1. Gene expression of (A) GLAST 
and (B) GLT-1 in globus pallidus, caudate-putamen, substania nigra, and cortex, where 
values are expressed as percent control ± S.E.M. with mean control values equivalent to 
“100%”. (A) No changes were found in GLAST gene expression. (B) A non-significant ~ 
20% increase in GLT-1 gene expression was observed in MnCr group of GP and CP, 
while no other changes were observed in other groups or other brain regions. 
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GPx, Catalase, and HMX-1 Gene Expressions 
Statistical significance trends for increased GPx gene expression were observed in 
Cr group of the SN (p=0.055) and in MnCr group of the CX (p =0.051), when compared 
to controls. No other changes were seen in GPx gene expression. No changes were found 
in catalase gene expression due to Mn or creatine treatments. For HMX-1 gene 
expression, a statistical trend towards an increase was seen in the Mn group when 
compared to MnCr in the GP (p=0.08). Also, in the SN, Mn group tended to have an 
increase in gene expression when compared to controls, however this increase was only a 
trend towards significance (p=0.072). No other changes were seen (Figure 4-4). 
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Figure 4-4: Gene Expression of GPx, catalase, and HMX-1. Gene expression of (A) 
GPx , (B) catalase, and (C) HMX-1 in globus pallidus, caudate-putamen, substania nigra, 
and cortex, where values are expressed as percent control ± S.E.M. with mean control 
values equivalent to “100%”. (A) No changes were obsereved with GPx gene expression, 
except for non-significant increase seen in Cr group of Sn and MnCr group of CX, when 
compared to controls. (B) No changes were seen in catalase gene expression. (C) An 
approximate non-significant 50% increase was observed in gene expression of HMX-1 in 
Mn group of GP.  
† 
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CRT-1, CK-BB, and CK-Mit1 Gene Expressions 
Gene expression of CRT-1 and CK-Mit1 were not altered in any treatment group 
compared to control. However, changes in CK-BB gene expression were observed in the 
CP, where it was significantly lowered in MnCr when compared to controls (p=0.007) 
Figure (4-5). 
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Figure 4-5: Gene Expression  of CRT-1, CK-BB, and CK-Mit1. Gene expression of 
(A) CRT-1, (B) CK-BB, and (C) CK-Mit1 in globus pallidus, caudate-putamen, substania 
nigra, and cortex, where values are expressed as percent control ± S.E.M. with mean 
control values equivalent to “100%”. (A) No changes were found in CRT-1 gene 
expression. (B) A significant decrease in CK-BB gene expression was observed in MnCr 
group of SN group (p>0.05), and a similar near-significant decrease was also seen in 
MnCr group of CP, no changes were observed in other groups. (C) No changes were seen 
for the gene expression of CKMit1. *p < 0.05 according to Dunnett’s post hoc analysis. 
* 
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Western Blot Analysis 
No Changes were observed in GLAST and GLT-1 proteins in GP and CP (Figure 
4-6). 
 
 
(A) Globus pallidus western blots 
 
 
 
 
 
 
 
 
 
(B) Caudate-putamen western blots 
 
 
 
 
 
 
 
 
 
 
Figure 4-6: Western Blots of GLAST and GLT-1 Proteins. (A) Globus pallidus. (B) 
Caudate-putamen. No significant changes were seen in GLAST and GLT-1 protein 
concentrations. 
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Total GSH 
Levels of glutathione remained unchanged in the CP, however, a slight non-  
significant decrease was observed in the GP (Figure 4-7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7: Total Glutathione Levels. Total glutathione levels in (A) globus pallidus, 
and (B) caudate-putamen, where values are expressed as percent control ± S.E.M. with 
mean control values equivalent to “100%”. (A) A non-significant decrease was observed 
in all groups in GSH levels when compared to control in the GP. (B) No changes were 
seen in the CP GSH levels. 
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Creatine Kinase Activity 
Although CK activity in the plasma increased in Cr group, this increase was not 
statistically significant. Furthermore, no changes were observed in Mn and MnCr groups 
despite the increase in plasma Mn concentrations (Figure 4-8) 
 
 
 
 
 
 
Figure 4-8: Creatine Kinase Activity in Plasma. Creatine kinase activity values 
expressed as percent control ± S.E.M. with mean control values equivalent to “100%”. 
No Changes were observed in Mn and MnCr groups, where as a non-significant increase 
was noted in the Cr group. 
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Discussion 
Manganese is known to induce GLU excitotoxicity through decreased GLU 
uptake by astrocytes ( Hazell and Norenberg, 1997). Alterations in gene and protein 
expression of both GLAST and GLT-1 have been reported previously in Mn-exposed 
nonhuman primates. Erikson et al. (2007) showed a pallidal increase in GLAST and 
GLT-1 gene expression with decreased GLAST proteins, and a decrease in GLT-1 
mRNA levels and protein in caudate. Meanwhile, in our study we report no significant 
changes in gene expression and protein levels of GLAST and GLT-1 in GP, CP, SN, and 
CX brain regions upon waterborne exposure to Mn, and our data corroborates the 
unaltered protein profiles found in monkeys that received weekly Mn injections (Burton 
et al., 2009). Furthermore, initial stages of altered GLU uptake may not necessary be due 
to changes in gene or protein expressions, rather it could be due to ion imbalance, 
especially that GLU transporters are dependent on intact Na+, K+, and H+ gradients 
(Billups et al., 1998; Choi, 1988), which may be disrupted in Mn toxicity (Scheuhammer 
and Cherian, 1981). It can be hypothesized that Mn may induce a post-translational 
modification of GLAST and GLT-1 proteins, or even it may bind non-competitively to 
these proteins therefore affecting their activity rather than concentrations (Hazell and 
Norenberg, 1997).  
Given its fatty composition, the brain is known to be highly vulnerable to lipid 
peroxidation, which is a marker of neurodegenerative diseases. Besides increased 
oxidative stressors in Mn neurotoxicity, antioxidant defense mechanisms have been 
repeatedly reported to be altered (Dobson et al., 2003; Taylor et al., 2006). Glutathione, 
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an antioxidant synthesized from L-cysteine, L-glutamic acid, and glycine, can scavenge 
free radicals to rid the cells of their potency to cause oxidative damage, where GPx is 
required for this process to occur. The GSH system in models of Mn neurotoxicity is 
altered, where inhalation studies of nonhuman primates have previously reported a 
decrease in GSH levels in the caudate post exposure to Mn, particularly in animals of 
older age (Erikson et al., 2007). Meanwhile in a different study, a sub-chronic oral 
exposure to Mn was found to decrease GSH levels in CP of aged rats, but increase it in 
younger ones (Desole et al., 1995). In our study we report that waterborne exposure to 
Mn causes no changes in total levels of GSH in the CP with a non-significant 
approximate 30% decrease in the GP. Findings in the CP corroborate a study by Dobson 
et al. (2003), where airborne exposure to Mn did not induce any changes in GSH levels of 
the CP in rats. However, a study published in 2008 showing a decrease in GSH levels in 
the caudate and an increase in the putamen of monkeys exposed to Mn, arouses the 
possibility that opposite changes in the caudate and the putamen may neutralize the 
results (Erikson et al., 2008). Furthermore, we assessed GPx gene expression and found 
no significant changes upon exposure to Mn corroborating a similar study conducted 
previously in our lab (unpublished data). The activity of catalase, an antioxidant, is 
reported to decrease in Mn neurotoxicity (Liccione and Maines, 1988); therefore it can be 
assumed that the gene expression of this enzyme will elevate upon increased ROS in the 
brain, we measured it in the four brain region, but found no changes affiliated with 
exposure to Mn.  
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Overexpression of HMX-1 is associated with increased oxidative stress, and has 
been documented in a number of neurodegenerative diseases such as Parkinson’s disease 
and Huntington’s disease (Schipper, 2004). Recently, Li and colleagues (2011) reported 
increased HMX-1 proteins in PC12 cells exposed to Mn that are possibly related to the 
activation of the NF-E2 factor 2 (Nrf2) signaling pathway by Mn. In our study we report 
a 50% non-significant increase in HMX-1 gene expression in GP (p = 0.240), and SN 
(p=0.072). Although these findings are not statistically significant, the overexpression of 
HMX-1, especially in the SN may indicate a possible role of HMX-1 in the progression 
of Mn-induced neurotoxicity, where there is an ongoing debate of whether the 
overexpression of HMX-1 is neuroprotective or is detrimental to cells by increasing labile 
Fe. 
Creatine is a nitrogenous organic acid that is important for energy maintenance in 
tissues with high fluctuating energy demands such as the brain, which depends on both 
endogenously synthesized creatine, and creatine obtained from the blood circulation via 
the blood brain barrier. Previous reports have shown a decrease in creatine content of the 
liver as well as the brain upon intoxication with Mn (Dorman et al., 2008; Fordahl et al., 
2011); therefore supplying an exogenous source of creatine may prevent such deficiency 
and enhance the energy status of the cell. In our study, treating Mn-exposed rats with 
creatine showed a slight enhancement of gene expressions of GLT-1 in GP and CP, GPx 
in CP, and HMX-1 in SN where these changes signify a neuroprotective role of creatine 
in reversing changes that are induced by Mn in the brain. While these changes were 
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mostly statistical trends, it is possible that the small sample size and the short duration of 
exposure to Mn have influenced our findings.  
Multiple mechanisms have been proposed for the therapeutic implications of 
creatine in neurodegeneration. It is thought that the contribution of creatine in generating 
ADP to provide a positive feedback on the electron transport chain decreases the release 
of ROS from the mitochondria, where this process is coupled to the mitochondrial CK 
(Meyer et al., 2006). Moreover, it has been suggested that the role of creatine in energy 
homeostasis not only decreases ROS generation and increases ATP supplies, but also 
imposes protection against the development of the mitochondrial permeability transition 
pore (PTP), which is one of the late events occurring in Mn cytotoxicity. This modest 
protection against PTP is also thought to be attributed to mitochondrial CK which is an 
octamor that is bound to the mitochondrial inner and outer membranes and is thought to 
be coupled with antinuclear translocase (Dodler et al., 2003; Speer et al., 2005). 
However, creatine administered to mitochondrial CK-deficient mice yielded significant 
neuroprotection against 1-methyl-1, 2, 3, 6-tetrahydropyridine toxicity indicating that the 
protective effects of creatine may be attributed to other mechanism or to the cytosolic CK 
rather than the mitochondrial (Klivenyi et al., 2004). In our study, we measured gene 
expression of both the cytosolic and the mitochondrial isoforms of CK as well as CRT-1, 
however no changes were found except for a significant decrease in CK-BB in MnCr 
group of the SN. Moreover, measurements of plasma creatine kinase activity only yielded 
a slight increase in activity in MnCr group with an approximate 30% increase in Cr 
group, where it was expected that Mn would decrease the activity of CK given its 
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cysteine-containing structure that makes it vulnerable to oxidants, as well as a the 
possible competitive binding of Mn to Mg-binding site on CK, where it is well 
documented that Mn interferes with the binding of Mg in multiple enzymes and receptors 
such as N-methyl-D-aspartate receptor (Chan et al., 1992) 
In conclusion, waterborne sub-chronic exposure to Mn in rats may not impose 
major neurochemical alterations related to GLU neurotransmitter transporters as well as 
to oxidative stress defense systems’ gene expression and protein concentrations, however 
it is obvious that this exposure initiates minor neurotoxic events within the CNS that 
involve HMX-1 enzyme. Furthermore, creatine treatment seems to have some sort of 
neuroprotection against Mn-induced neurotoxicity, yet there is a need to investigate the 
use of higher dosage in different models of Mn-exposure and perhaps with the use of 
intracranial or oral administration of creatine. 
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CHAPTER V 
EPILOGUE 
 
 
Despite the essentiality of manganese (Mn) to biological systems, excess Mn is 
detrimental to normal neurological health of human beings. Manganese-induced 
neurotoxicity is marked with pallidal cell loss and degeneration that follows disruption of 
the basal ganglia inhibitory and excitatory neurotransmission pathways, where Mn 
interferes with neurotransmitter transport system as well as enzymatic activity of 
neurotransmitter-metabolizing enzymes, such as glutamine synthetase (Erikson and 
Aschner, 2003; Fitsanakis et al., 2006). Another deleterious feature of Mn neurotoxicity 
is increased generation of reactive oxygen species and the subsequent oxidative damage 
that hinders astrocytic and neuronal functioning (Taylor et al., 2006; Milatovic et al., 
2009). These changes, along with Mn-induced mineral and ion imbalance, contribute to 
energy failure and to induction of apoptosis, thereafter causing neurodegeneration 
(Scheuhammer and Cherian, 1981; Zwingmann et al., 2003). 
The purpose of this study was to further characterize the effect of Mn 
accumulation on glutamate (GLU) transport system, and on endogenous antioxidant 
systems with and without the administration of the energy substrate creatine. We 
examined the effect of pre- and post creatine treatment on survival of Mn-exposed 
astrocytes, and measured mRNA levels of glutamate-aspartate transporter (GLAST), 
glutathione peroxidase (GPx), and creatine transporter-1 (CRT-1). We also assessed 
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creatine therapy during waterborne Mn exposure in rats, and measured end points to 
assess changes in GLU transporters, oxidative stress markers, and creatine function.  
We found that creatine enhanced cellular survival especially when administered 
prior to Mn exposure in astrocytes despite elevated intracellular Mn levels. Meanwhile, 
the marked increase that we observed in GLAST gene expression must be interpreted 
with caution. This is because GLAST expression in tissue could be influenced by 
neuronal-glial interactions, where the regulation of GLU transporters gene expression is 
influenced by many factors that include GLU extra- and intracellular concentrations 
(Billups et al., 1998; Ye and Sontheimer, 2002). Moreover, our results showed that 
astrocytes exposed to both creatine and Mn had a decrease in GPx gene expression, 
which brings about a question regarding the oxidative stress status of the cells when 
treated with Mn and creatine. Interestingly, the available literature on creatine contradicts 
itself, where some researchers suggest antioxidant activity of creatine (Fimognari et al. 
2009), while others propose its contribution to increased ROS generation (Juravleva et 
al., 2005). Therefore, a direct measure of free radical concentrations would further clarify 
the protective effects of creatine.  
Oral exposure to Mn did not induce significant changes in GLAST and GLT-1 
protein regardless of the significant elevation in Mn concentrations, namely in the globus 
pallidus and the caudate-putamen. This lack of change could be due to a short duration of 
exposure to Mn (42 days) which might not have allowed enough time for protein turnover 
to occur and therefore to demonstrate changes. Furthermore, past studies have 
demonstrated that the different forms of Mn and different routes of exposure may have 
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different absorption trends and accumulation patterns in the CNS, and therefore perhaps 
may have different neurotoxic behaviors (Roels et al., 1997). However, for more accurate 
measurements of the influence of Mn on GLU transporters, it is preferable to measure 
protein activity levels instead of total protein content. Changes in some oxidative stress 
markers were also minimal following waterborne Mn exposure mainly in the GSH and 
catalase antioxidant systems. Alteration in total GSH is documented to be age- and sex-
dependent, where older animals tend to have an overall decline in the brain’s basal GSH 
concentrations (Maher, 2005). Moreover, it is important to point out that our 
measurements of total GSH did not designate levels of oxidized versus reduced GSH, 
which may not necessary reflect true status of GSH in the tissue. Meanwhile, our novel 
finding of a near significant Mn induction of gene expression of HMX-1 corroborated 
previous data on the role of Mn in activating NF-E2 factor 2 (Nrf2) signaling pathway 
that up-regulates HMX-1 expression (Li et al., 2011), bringing forth more questions 
about the role of HMX-1 in oxidative stress and altered iron metabolism in Mn 
neurotoxicity.  
While the administration of creatine treatment showed effectiveness in astrocyte 
cell cultures, it caused no or minimal non-significant changes in the Mn-exposed rat 
brain. This could be attributed to the low dosage of creatine used; especially that creatine 
monohydrate is characterized with low solubility in aqueous solutions that renders the 
application of high dosage if administered via intraperitoneal injections. Additionally, a 
previous study using the maximum soluble creatine concentrations revealed that 
intraperitoneal injections only increase the brain’s concentrations by 70 μM, which is not 
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high enough to have a therapeutic impact on the brain (Perasso et al., 2003). Meanwhile, 
it is possible that intracerebroventricular administration of creatine may increase the 
brain’s creatine levels, where this increase has been found comparable to creatine 
concentrations needed for protection against ischemia (Rebaudo et al., 2000). The use of 
a different creatine-derivative may also be another alternative for examining the 
protective role of creatine in vivo models of Mn neurotoxicity. For instance, 
phosphocreatine-Mg complex acetate is a creatine derivative that has been found to cross 
the blood brain barrier and protect against ischemia in mice (Perasso et al., 2009).  
Our findings suggest that creatine has some neuroprotection against Mn-induced 
neurotoxicity, similar to that seen in other neurodegenerative diseases. However, the 
mechanisms of action for neuroprotection remain unclear and demand further 
investigation. Despite the effect of creatine on cell survival on Mn-exposed astrocytes, it 
is important to measure the uptake of creatine to determine the dosage required to obtain 
neuroprotection. This may help with determining an effective dose to be used in animals. 
Furthermore, with existing evidence of neuroprotective role of creatine against 
excitotoxicity in other neurodegenerative diseases (Bender et al., 2005; Andreassen 
2001b), it is important to determine GLU uptake and concentrations in models of Mn 
neurotoxicity that are treated with creatine. Because creatine was found to protect N-
methyl-D-aspartic acid (NMDA) receptor against neurodegeneratione (Malcon et al., 
2000), and since this receptor alteration in Mn neurotoxicity contributes to induction of 
excitotoxicity and ion imbalance, it is worthwhile to assess the influence of creatine on 
NMDA in Mn-induced neurodegeneration.  
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